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ABSTRACT 
 
Display of random peptides on the surface of filamentous bacteriophage allows 
identification of ligands to virtually any target. We have examined here new strategies to 
improve the phage display-derived peptides and to expedite their development into drug-
leads. This has been achieved by integrating phage display with a recombinant peptide 
expression and by incorporating amino acid analogues into soluble peptides and peptides 
displayed on phage. We have also utilized phage for screening a small-molecule compound 
library. 
 
We have studied the migration and invasion mechanisms of neoplastic cells by inhibition of 
matrix metalloproteinase (MMP)-2 and –9 functions with the phage display derived 
peptides. In addition to improving the stability of a gelatinase inhibitor peptide, we have 
found several new strategies to interfere with gelatinase functions. A peptide mimicking a 
sequence in the catalytic domain of the gelatinases bound to the αM and αL I domains of the 
leukocyte integrins and inhibited leukemia cell migration. Biopanning with proMMP-9 
identified a novel and selective inhibitor of gelatinases. By similarity to this peptide we 
identified a gelatinase-recognition motif in the extracellular matrix proteins fibronectin and 
vitronectin. A peptide blocking the interaction of the C-terminal domain of MMP-9 with 
cell surface β5 integrins was found to be an efficient inhibitor of HT1080 fibrosarcoma cell 
migration and invasion although it did not affect MMP-9 activity in vitro. The binding site 
of the C-terminal domain of MMP-9 in the integrin could be identified by sequence 
similarity, and it was located to an activation epitope in the stalk of the integrin β chain, and 
not the typical integrin ligand-binding region. The C-terminal domain-binding peptide also 
blocked the migration of leukemia cells by binding to the β2 integrin subunit and inhibited 
the plasminogen/MMP-3 dependent activation of MMP-9. Urokinase plasminogen activator 
(uPA) and the urokinase receptor (uPAR) are responsible for the cell surface activation of 
plasminogen and critically involved in cell migration and tumor metastasis. We observed an 
interaction of uPAR with MMP-9 and found that uPAR was cleaved by MMP-9. In 
addition, the C-terminal domain-binding peptide inhibited human tumor xenograft growth in 
a mouse model indicating a novel utility for MMP-9 inhibitors, which do not inhibit 
enzymatic activity. 
 
As an alternative to the modification of phage display peptides, a small-molecule compound 
library was screened to identify chemicals that would compete with the αM I domain-binding 
peptide. This screen identified a novel compound that potently inhibited phage binding to 
the αM integrin I domain, but did not inhibit but rather increased proMMP-9 binding to this 
domain. In addition, we found that this compound increased the resistance of leukemia cells 
to detachment from αMβ2 integrin ligands and that this compound potently inhibited αMβ2 
integrin-dependent leukemia cell migration without affecting gelatinase activity. 
 
In summary, we have identified molecular details for several interactions between MMP-9 
and various cell surface and extracellular matrix molecules. Our results show that these 
interactions plays an important role in the motility of neoplastic cells and that prevention of 
these interactions inhibits cancer cell migration and invasion. However, our research with 
the chemical inhibitor of leukemia cell migration indicates that gelatinase-independent 
mechanisms for cell migration exist implicating a possible need for additional treatment 
strategies to completely inhibit cancer cell motility. 
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INTRODUCTION 
 
PHAGE DISPLAY 
 
Phage display formats 
 
The bacteriophage M13, Fd and other related filamentous bacteriophage are the most 
commonly used vectors for phage display, although other phage such as T7 phage and λ 
phage have also been successfully used (Kuwabara et al., 1997; Laakkonen et al., 2002). 
The filamentous bacteriophage are single-stranded DNA containing viruses infecting many 
gram-negative bacteria, which harbor a F pilus. The virions are rod-like, the width being 
approximately 6.5 nm and the length 900-2000 nm, depending on the genome size 
(Glucksman et al., 1992; Model and Russel, 1988). The filamentous phage genome is 
relatively compact containing eleven genes, which encode for the capsid proteins and 
proteins required for DNA replication and virion assembly (Model and Russel, 1988). The 
single stranded DNA is packed into virions on the membrane of the bacterial host with the 
aid of assembly proteins of the phage and the host proteins such as thioredoxin (Marciano et 
al., 1999; Russel and Model, 1985). The completed phage particle contains a single major 
coat protein, pVIII present in about 2900 copies. Additionally, one end of the phage particle 
contains two minor coat proteins pIII and pVI and the other end pVII and pIX proteins in 
about 2-5 copies each (Makowski, 1992, Uppala and Koivunen, 2000). 
 
In the mid-1980’s George Smith demonstrated that foreign polypeptides could be expressed 
as a fusion with the minor coat protein pIII and used to find information about antibody 
epitopes by affinity selection of the phage that bound to an antibody (Parmley and Smith, 
1988; Smith, 1985). The novelty of this method was that each particle carried the coding 
information of the displayed polypeptide in their genome thus facilitating the identification 
of the binding epitope. Individual antibody-binding phage could be easily identified using 
standard microbiological techniques and amplified in E. coli to isolate sufficient quantities 
of DNA for sequencing. By cloning oligonucleotides containing degenerate codons, a 
random library of peptides was constructed, each phage carrying a single peptide on the coat 
protein (Scott and Smith, 1990). These unconstrained, completely random peptide libraries 
are typically referred as linear peptide libraries. It is also possible to constrain the peptide 
libraries by fixing certain amino acids in predetermined positions. For example, cyclic 
disulfide-constrained libraries are obtained when two cysteines flank the otherwise random 
sequence. Due to the structural constrain, the cyclic peptides are typically of higher affinity 
than the more flexible linear peptides (Koivunen et al., 1993; McLafferty et al., 1993). 
 
Antibodies, enzymes, growth factors and many other large proteins have also been 
expressed as a fusion on the minor coat protein pIII (Lowman et al., 1991; McCafferty et 
al., 1990; McCafferty et al., 1991). The display of antibodies and other larger proteins can 
be used to isolate high-affinity binders or to isolate variants with specific properties. 
Although antibodies can be efficiently displayed in a single chain form and as Fab 
fragments, the display efficiency of other proteins varies considerably limiting the use of 
filamentous phage in cDNA library screenings (Hufton et al., 1999). Other coat proteins of 
the phage have also been used for display of peptides and proteins. The most commonly 
used alternative is the pVIII major coat protein (Felici et al., 1991). The advantage of the 
pVIII display is that the peptides are displayed in much higher number leading to avidity 
effects. The disadvantage is that the packaging of the phage is often disturbed especially by 
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large insertions. Thus, hybrid phage with both wild type and recombinant pVIII proteins are 
commonly used (Greenwood et al., 1991). All the other coat proteins of the filamentous 
bacteriophage can and have been utilized for phage display. The pVII and pIX minor coat 
proteins have been used together for two-chain antibody display (Gao et al., 1999) and pVI 
display for peptide and cDNA display. In contrast to the pIII and pVIII display systems, the 
C-terminus of the pVI protein projects outwards and allows display of peptides and proteins 
with a free C-terminus (Hufton et al., 1999). Unexpectedly, the C-terminus of the pIII and 
pVIII proteins have also been successfully used for peptide display in a phagemid format 
(Fuh et al., 2000; Fuh and Sidhu, 2000).  
 
Biopanning with phage display libraries 
 
Basically, phage display is based on affinity selection to enrich specifically binding phage 
over a huge excess of irrelevant phage (Figure 1). In the simplest form phage are allowed to 
bind to an immobilized target, unbound phage are washed away and the bound phage are 
eluted using a low pH buffer or a known competitive ligand. It is also possible to use 
biotinylated or otherwise tagged target proteins and allow them to react with the phage in 
solution followed by affinity capture of the target and the bound phage. The eluted phage 
are then allowed to infect bacteria and are then amplified and recovered using a 
polyethylene glycol-sodium chloride precipitation. Successive rounds with the enriched 
phage preparations are done until a sufficient enrichment of specifically bound phage is 
achieved (Koivunen et al., 1999). The most critical issue in biopanning is a careful design 
and control over the selection conditions, because the method selects for the best binders in 
the used condition, which is not necessarily a physiologically relevant one. 
 
 
Figure 1. The biopanning procedure using an 
immobilized target molecule. The biopanning cycle 
consisting of binding, washing and elution steps is 
repeated until a sufficient enrichment of specifically 
bound phage is achieved, usually after 2-5 rounds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 10
It is also essential that the target is in an active form. In some cases the target protein may 
not be purified in a native form necessitating the use of specific selection schemes. Indeed, 
the target molecule does not need to be pure. With an appropriate selection design, it is 
possible to enrich peptides to a target present in a complex environment such as a cell 
surface or in a tissue biopsy (Goodson et al., 1994). A subtractive step with a similar 
prepararation, but lacking the target molecule, for example, cells not expressing the specific 
receptor or an immunodepleted protein mixture, is used to eliminate non-target binding 
sequences from the initial library. Thereafter the unbound phage are transferred to the 
mixture containing the target to enrich the specifically binding clones. 
 
Applications of peptide display 
 
Although phage display was originally developed to identify antibody epitopes, phage 
display libraries are now widely used to identify peptide ligands to various proteins and 
other biomolecules (Goodson et al., 1994; Healy et al., 1995; Koivunen et al., 1999; 
Koivunen et al., 1993; Koivunen et al., 2001). Phage display is by no means limited to 
biological targets as peptides binding to semiconducting and magnetic materials can be 
isolated as well (Mao et al., 2004; Whaley et al., 2000). In an optimal case, isolation of the 
peptide ligands allows the identification of a binding partner for the target protein together 
with the interacting sequence. However, when synthetic degenerate peptide libraries are 
used, the peptide ligands rarely exactly match with a natural protein sequence. In addition, 
the short peptides commonly show similarities to a wide variety of proteins, and often only 
three or four amino acid residues in the peptide are directly involved in target binding, 
whereas the rest may be structurally required or have no specific function. Hence, in the 
absence of any information about possible binding partners a high rate of false positive 
interactions are typically obtained from database searches possibly masking the true 
interactions (Smothers and Henikoff, 2001). Such problems can be avoided by displaying 
randomly fragmented cDNA (Matthews et al., 2002). 
 
One application of the phage peptide libraries is the mapping of substrate recognition sites 
for proteases. Protease cleavage sites can be found using substrate phage immobilized on a 
solid support. Addition of an active protease releases only the phage containing a substrate 
recognition sequence. These phage can then be amplified and further enriched to determine 
the optimal substrates for the protease of interest. This technique has been used to map the 
cleavage sites of subtilisin (Matthews and Wells, 1993), furin (Matthews et al., 1994) and 
several matrix metalloproteinases (MMPs) (Chen et al., 2002; Deng et al., 2000; Kridel et 
al., 2001; Kridel et al., 2002; Smith et al., 1995). Not only protease substrates can be found 
using phage display. It is well established that the phage-display selected peptides 
commonly bind to biologically relevant sites in the targets such as the catalytic site of 
enzymes or ligand-binding site of receptors. This is because a small peptide has to form 
contacts with relatively large areas in the target in order to have sufficient binding affinity. 
The active sites of the enzymes and the ligand-binding sites of the receptors typically form 
suitable large clefts, crevices or holes with some flexibility to accommodate the 
substrates/ligands (Kay and Hamilton, 2001). The peptide CTTHWGFTLC (CTT), which 
binds to the gelatinases MMP-2 and MMP-9 is a model example of a phage display peptide 
that also acts as a potent inhibitor (Koivunen et al., 1999). A large number of other enzyme 
inhibitors have been discovered including enzymes, which normally have non-protein 
substrates (Kay and Hamilton, 2001). 
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Biopanning is by no means limited to in vitro and ex vivo applications. Phage display can be 
equally well performed in vivo. Here, the phage library is injected into the blood stream of 
an organism, and the phage are subsequently recovered from the individual organs. 
Remarkably, this method has permitted the isolation of peptides that home to specific 
organs in mice without a prior knowledge about the target molecules present in the organ 
vasculature (Pasqualini and Ruoslahti, 1996). The in vivo display has also been performed in 
human subjects (Arap et al., 2002) and other organisms such a mosquitos (Ghosh et al., 
2001). The in vivo display offers an exciting route to develop peptides homing to specific 
locations, such as the tumor vasculature (Ruoslahti, 2000). The homing peptides obtained by 
in vivo display can be used to deliver various cargo such as cytotoxic drugs, proteins, 
liposomes, imaging agents and viruses into specific sites in an organism (Akerman et al., 
2002; Arap et al., 1998; Curnis et al., 2000; Medina et al., 2001; Turunen et al., 2002). The 
advantage of the targeting approach is that it minimizes the adverse effects of the drugs or 
other cargo in non-target organs. 
  
Analysis of phage peptides 
 
One of the current bottlenecks in the phage display selections is the functional analysis of 
the target-binding sequences. A single phage selection typically yields multiple potential 
peptide ligands from which the most suitable candidates should be selected. Although the 
selections could in principle be continued until a single sequence remains, this is rarely a 
favorable practice as the affinity of the binding sequence is not the only selective force in 
the biopannings. For example, the effect of the displayed peptides on phage particle 
production may significantly favor the selection of some sequences. Optimally, one would 
like to determine all different peptide motifs binding to a target and not to introduce any 
bias in the selections. Another issue is that the selected peptides may not be sufficiently 
soluble for the intended purposes. It is thus advantageous to analyze the sequences from the 
early rounds of selections to get maximal information on the binding sequence motifs and to 
obtain sufficiently diverse selection of peptides for activity analysis. Furthermore, by 
alignment of the phage peptides, consensus sequence motifs are obtained and these rather 
than single sequences can be used to search for putative binding partners allowing filtering 
of the false positive interactions (Deshayes et al., 2002; Smothers and Henikoff, 2001). 
However, having a multitude of target binding sequences possesses a practical problem, 
because one should be able to analyze the peptides for biological activity. Traditionally, 
phage peptides have been prepared as fusions with larger proteins such as glutathione-S-
transferase (GST) (Rajotte et al., 1998) or alkaline phosphatase (Wright et al., 2001). 
However, with this approach it is often difficult or impossible to obtain peptide 
concentrations sufficient to demonstrate the biological activity of a peptide such as enzyme 
inhibition. Furthermore, it is also impossible to analyze the solubility properties of the 
peptides. Hence, one would preferably analyze a reasonable number of different peptides as 
such without any fusion tags. Chemical peptide synthesis is rather expensive and often only 
small quantities of peptides would be sufficient for the initial analysis. Although high-
throughput peptide synthesis methods have been developed (Pipkorn et al., 2002), they may 
not be easily available. In these cases recombinant methods to produce the peptides are a 
competitive alternative. 
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Recombinant protein expression using self-splicing inteins 
 
Inteins are a group of proteins with intrinsic self-cleavage ability originally found in yeast 
(Kane et al., 1990), and are the proteinaceous equivalents for introns in RNA. Inteins are 
cleaved from the precursor proteins with the concomitant joining of the intein-flanking 
polypeptides (the exteins) to form a functional protein (Paulus, 2000). Due to the 
controllable autocatalytic trait of the inteins, they are now used as fusion partners for 
recombinant protein expression (Chong et al., 1997; Chong et al., 1998). The advantage is 
that it is possible to use the intein in affinity purification and then through a controlled 
protein cleavage obtain the protein of interest in a native form without any extraneous 
amino acid sequences. The intein cleavage occurs under mild conditions and avoids the use 
of proteinases or peptide bond-cleaving chemicals, which often have adverse effects on 
recombinant proteins (Chong et al., 1997). 
 
The intein cleavage occurs through a series of intramolecular reactions at the intein-extein 
junction. The rearrangement of the peptide bonds results in the formation of a reactive 
thioester, which can be cleaved with thiol compounds, such as cysteine or dithiotreitol 
(Paulus, 2000). Mutant inteins displaying cleavage activity in the absence of thiols have also 
been isolated (Mathys et al., 1999). The cleavage activity of these proteins can be 
modulated by pH and temperature control. An additional benefit of the inteins as a fusion 
partner is that the unique reactivity of the thioester bond can be exploited for a selective 
modification of the expressed protein. By utilizing this trait, site-selective biotinylation 
(Lesaicherre et al., 2002), C-terminal amidation (Cottingham et al., 2001), backbone 
cyclization via a native peptide bond between the N- and the C-terminus of the protein 
(Evans et al., 1999; Scott et al., 1999) and addition of non-natural amino acids (Severinov 
and Muir, 1998) into recombinant proteins has been accomplished. 
 
The self-cleavage of the inteins makes them attractive fusion partners for peptide 
expression. Furthermore, minimal inteins with full cleavage activity have only 130-160 
amino acids (Derbyshire et al., 1997; Mathys et al., 1999; Wood et al., 1999). With a 
minimal sized fusion partner, the protein expressing cells do not have to consume their 
metabolic reserves for expressing large unwanted proteins thus maximising the peptide 
yield. 
Biosynthetic methods for incorporation of novel amino acids 
 
Phage display has been highly successful in the identification of surrogate ligands for 
various proteins, because it does not require any structural knowledge about the target. Nor 
are extensive screenings required as with the chemical compound libraries. Typically a few 
microtiter wells coated with submicrogram quantities of the target protein are sufficient to 
yield the desired peptide ligands. However, more and more structural information of the 
proteins is becoming available and the availability of compound libraries increases together 
with the development of improved screening methodologies, including the in silico 
screenings (Bajorath, 2002; Engels and Venkatarangan, 2001). These advancements are 
significantly simplifying and accelerating the discovery of small-molecule ligands. 
Furthermore, the inherent proteinaceous nature of the biological display library-derived 
ligands poses another problem as peptides are often rapidly degraded and/or cleared from 
the circulation and may require extensive modifications to extend their utility in vivo 
(Adessi and Soto, 2002; Lien and Lowman, 2003). 
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The ability of E. coli to incorporate nonproteinogenic amino acids into polypeptides has 
been known for decades (Cowie and Cohen, 1957; Fenster and Anker, 1969; Hagen et al., 
1978; Hagen et al., 1979; Rennert and Anker, 1963), but this property has only recently 
been exploited for the modification of recombinant proteins. The two main strategies are the 
residue-specific incorporation of nonnatural amino acids by misaminoacylation of transfer-
RNAs (tRNAs) (Kiick et al., 2001; Kirshenbaum et al., 2002; Niemz and Tirrell, 2001) and 
the site-directed incorporation, which utilizes non-cognate amber suppressor 
tRNA/aminoacyl-tRNA synthetase pairs (Noren et al., 1989; Wang et al., 2001). The 
significance of these methodologies is that by incorporation of nonnatural amino acid 
residues proteins or peptides can be modulated to have enhanced metabolic and/or thermal 
stability and/or increased activity (Tang et al., 2001; Tang and Tirrell, 2001). Alternatively, 
novel functional groups such as fluorescent probes (Cornish et al., 1994), amino acids with 
side chains containing chemically modifiable groups (Kiick et al., 2002) or photoaffinity 
labels for cross-linking (Chin et al., 2002) can be added. In the context of phage display the 
addition of novel amino acids could increase the peptide diversity leading to the discovery 
of peptides with higher activity and other desired properties, such as increased stability. 
 
In addition to aforementioned two methodologies, it is possibly to modify ribosomes to 
accept D-amino acid isomers instead of the normal L-amino acids (Dedkova et al., 2003). 
This approach utilizes ribosomes that have been formed when a mutated 23S ribosomal 
RNA is expressed in high levels in E. coli. These mutant ribosomes, which tolerate D-amino 
acids can be isolated and used in protein synthesis in vitro. The ribosomes are, to some 
extent, able to accept amino acids with peptide-backbone modifications. These approaches 
concentrating on the modification of ribosomes may significantly contribute to the chemical 
diversity of the in vitro display systems (Frankel et al., 2003). In principle, non-ribosomal 
peptide synthesis is another possible route for the biosynthesis of highly modified peptides 
(Cane et al., 1998; Velkov and Lawen, 2003). However, the existing applications have been 
focused on the modification of naturally-occurring non-ribosomally synthesized peptides 
and it may be difficult to adopt this methodology for the synthesis of custom peptides. 
 
Residue-specific incorporation of non-canonical amino acids by misaminoacylation 
 
The misaminoacylation of tRNAs with amino acid analogues requires that the protein 
expression host, typically E. coli, is auxotrophic for the amino acid to be replaced. This 
means that the host must be deficient of synthesizing a particular amino acid. Many amino 
acid auxotrophic bacterial hosts are available or they can be readily prepared by 
mutagenesis. The misaminoacylation systems rely on the culture of these auxotrophic 
bacteria in a defined culture medium. Before the induction of protein expression, the 
bacteria are changed to a culture medium lacking the amino acid to be replaced, and a 
suitable amino acid analogue is added (Ibba and Hennecke, 1995; Kiick et al., 2001; Tang et 
al., 2001). The tRNAs to the particular amino acid are misaminoacylated with the analogues 
and subsequently incorporated into the expressed proteins. One noteworthy application of 
this method is the ability to incorporate selenomethionine into proteins. This has 
significantly helped in solving X-ray structures by the multiwavelenght anomalous 
diffraction method (Budisa et al., 1995; Hendrickson et al., 1990).   
 
Although the residue-specific method is simple and allows the incorporation of a wide 
variety of amino acid analogues, the disadvantages of this methodology are obvious. First, a 
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defined culture medium is needed, which typically results in significantly decreased protein 
yields. Second, the amino acid analogues must be structurally similar to the parental amino 
acid so that the aminoacyl-tRNA synthetase will accept them and attach them to the tRNAs. 
Third, this method replaces a single amino acid rather than expands the amino acid 
repertoire.  One additional issue of concern is that some amino acid analogues are toxic to 
the cells thus reducing their utility in protein expression, although tolerant mutant bacteria 
can be isolated (Bacher and Ellington, 2001). Of the many amino acid analogues that can be 
incorporated by misaminoacylation, fluorinated analogues of tyrosine, tryptophan, 
phenylanine, and leucine have been the most widely used (Hagen et al., 1978; Minks et al., 
1999; Minks et al., 2000; Rennert and Anker, 1963). Indeed, fluorine substitution offers 
many advantages. Due to the small size of the fluorine atom, the fluorinated analogues fit 
well to the active site of the aminoacyl-tRNA synthetases resulting in a high 
misaminoacylation rate. The fluorine atom also changes fluorescence properties of the 
aromatic amino acids allowing monitoring of the chemical environment of these residues 
(Minks et al., 2000). Additionally, the fluorine-substituted amino acids are more 
hydrophobic than the normal amino acids (Yoder and Kumar, 2002). As a result, proteins 
with fluoroamino acids often show an increase in thermal stability (Tang et al., 2001; Tang 
and Tirrell, 2001) and/or increased resistance to proteases and improved bioavailability 
(Hsieh et al., 1987). For these reasons, fluorine substitutions are also used in chemical 
compounds as a final push to increase their activity as exemplified by the MMP-2/αVβ3 
integrin interaction-inhibiting molecule (Boger et al., 2001). 
 
The constrains of the misaminoacylation system can be relaxed in several ways. Significant 
incorporation of structurally diverse phenylalanine analogues was achieved by 
overexpression of the wild type aminoacyl-tRNA synthetase (Kiick et al., 2000). Another 
strategy involves mutant synthetases with an enlarged substrate-binding site to 
accommodate those analogues that would not otherwise fit to the active site (Ibba and 
Hennecke, 1995). A third strategy is to modify the hydrolytic editing activity of the 
aminoacyl-tRNA synthetases so that the misaminocylation is not recognized as an error 
(Doring et al., 2001). An interesting modification of the misaminoacylation system is not to 
replace a single amino acid with an analogue, but to re-assign only a single codon to code 
for an analogue and thus break the degeneracy of the genetic code (Kwon et al., 2003). This 
approach may become highly useful as it does not replace an amino acid completely but 
expands the amino acid repertoire.   
 
Site-directed incorporation of unnatural amino acids 
 
In the site-directed approach the aim is to modify a single site in the protein rather than 
replace all amino acid residues. The key requirements for the site-directed incorporation of 
amino acid analogues are 1) a codon assigned for the site-selective insertion, 2) a tRNA that 
does not interact with the endogenous aminoacyl-tRNA synthetases, and 3) a method to 
acylate the corresponding tRNA with a desired amino acid analogue (reviewed by Anthony-
Cahill and Magliery, 2002). Typically, the codon that is re-assigned for the insertion is one 
of the three existing stop codons UAG, amber; UGA, opal; or UAA, ochre, the amber 
suppression being the most commonly used. It is also possible to assign four base-pair 
codons as a signal for the analogue incporporation (Magliery et al., 2001). The first site-
directed amino acid incorporation methods relied on chemically acylated tRNAs, which 
were added to the in vitro translation systems (Noren et al., 1989). Subsequently, through 
microinjection of aminoacylated tRNAs, membrane proteins could be tagged in vivo with 
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unnatural amino acids in Xenopus oocytes (Nowak et al., 1995). The next step was to make 
this system even more simple and effective by selecting for aminoacyl-tRNA synthetases, 
which could aminoacylate the tRNAs in vivo. As mentioned above, this required that the 
new aminoaminoacyl-tRNA synthetase could not use any naturally occurring amino acid as 
a substrate. These goals were achieved by the preparation of aminoacyl-tRNA synthetase 
mutant libraries from yeast and archaebacteria, and double-selection schemes with a 
negative and positive selection step to eliminate those enzymes that were capable of using 
naturally occurring amino acids and enriching those that were able to utilize the unnatural 
ones (Liu and Schultz, 1999). 
 
These findings and technological developments have led to the site-directed amino acid 
incorporation into proteins expressed in bacteria (Furter, 1998; Wang et al., 2001). A further 
refinement of this system is to evolve the bacteria to autonomouly synthesize the required 
amino acid analogue. A bacterial strain that contains the aminoacyl-synthetase incorporating 
p-aminophenylalanine and the biosynthetic gene to produce the p-aminophenylanine has 
been developed (Mehl et al., 2003). One of the interesting applications of the site-specific 
incorporation is the possibility to attach glycosyl groups into E. coli proteins (Liu et al., 
2003; Zhang et al., 2004). Such an approach could be very useful for the biotechnology 
industry due to the simplicity and efficacy of E. coli expression. In addition, the site-
directed amino acid analogue incorporation can also be directly applied to eukaryotic 
expression systems, including mammalian cells (Chin et al., 2003; Sakamoto et al., 2002). 
  
The residue- and site-specific strategies can be viewed as two complementary methods. 
Whereas the global misaminoacylation strategy aims to change the overall properties of the 
proteins, the site-directed incorporation strategy allows more subtle and specialized changes 
in the proteins (Link et al., 2003). It can be speculated that a combination of these strategies 
could be used to produce extensively modified recombinant proteins for pharmaceutical and 
other applications. 
  
Current approaches to increase the chemical diversity of biological display 
libraries 
 
The application of the amino acid analogue incorporation technologies into biological 
display libraries is expected to combine the beneficial features of biological display libraries 
and combinatorial chemistry, namely the powerful biological selections with the large 
chemical diversity. There has already been significant progress towards increasing the 
chemical diversity of the biological display libraries beyond the twenty canonical amino 
acids. 
  
Using in vitro phosphorylation of phage display peptide libraries, kinase substrates have 
been isolated. In this approach, phage that carry a kinase recognition sequence are 
phosphorylated and are enriched using phosphospecific antibodies (Gram et al., 1997; 
Schmitz et al., 1996). A similar approach has been utilized to identify phosphatase substrate 
sequence specificities (Walchli et al., 2004). Another in vitro amino acid modification 
approach is the ligation of synthetic unnatural amino acid containing peptides into phage 
displayed partially randomized proteins (Dwyer et al., 2000). Selenocysteine can be 
incorporated into phage particles by using a specific, naturally occurring selenocysteine 
insertion sequence. The selenocysteine residue can be selectively alkylated without affecting 
other residues including cysteines, thus offering a possibility for a site-specific modification 
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of a single amino acid in the displayed polypeptide (Sandman and Noren, 2000). It is also 
conceivable that the other noncanonical proteinogenic amino acid, pyrrolysine, could be 
similarly incorporated into phage particles (Namy et al., 2004; Srinivasan et al., 2002). The 
site-specific amino acid analogue incorporation method has also been applied to phage 
display. Although the purpose was to use phage as a tool to select for potent amber 
suppressor tRNA/aminoacyl-tRNA synthetase pairs for efficient incorporation of unnatural 
amino acids (Pastrnak and Schultz, 2001), this work demonstrates the feasibility of this 
approach in the context of phage display. Similarly, the misaminoacylation method can be 
utilized for the incorporation of amino acid analogues into phage proteins. This was already 
demonstrated in the 1970’s, when fluorinated tyrosine and phenylalanine analogues were 
added to the major coat protein of the M13 phage for NMR analysis (Dettman et al., 1982; 
Hagen et al., 1978; Hagen et al., 1979). The most advanced approach of increasing the 
chemical diversity of the phage display libraries involves attachment of a synthetic 
compound library on phage particles in such a manner that information about the chemical 
structure is encoded in the phage genome. Using this approach, folate receptor binding 
compounds were identified (Woiwode et al., 2003). 
 
Ribosome display, tRNA display and mRNA display systems also have the potential to 
incorporate various amino acid analogues, either by sense or nonsense suppression or 
chemical derivatization (Frankel et al., 2003). Using the latter method, a peptide-penicillin 
library was constructed and screened for active penicillin-derivatives (Li and Roberts, 
2003). Currently these in vitro display systems have the largest potential to incorporate 
amino acid analogues, because structurally diverse amino acid analogues can be 
conveniently linked to the tRNAs by chemical means, and because the in vitro systems do 
not suffer from toxicity problems caused by the nonnatural amino acids. 
 
A particularly exciting combination of phage display and small-molecule compound 
libraries is to first select for peptides binding to a target protein and then screen a small-
molecule library for compounds that compete with the phage peptide binding. If reasonably 
diverse compound libraries are available, this may be the most straightforward path from the 
phage display peptides to drug candidates as it circumvents the need for the tedious 
chemical modifications of the peptides. The feasibility of this approach was verified in three 
different binding assays using phage display-derived peptides and known chemical 
inhibitors of Haemophilus influenzae tyrosyl-tRNA synthetase (Hyde-DeRuyscher et al., 
2000). A library of 250 000 compounds has now been screened using this methodology to 
identify E. coli FtsZ/ZipA protein-protein interaction inhibitors. Among the screened 
compounds, 29 hits were found (Kenny et al., 2003). This approach offers a direct way to 
assay for small molecules in the absence of structural, or practically any other information 
about the target protein. In addition, target validation can be conveniently done with the 
peptides before conducting large screening programs to search for the small-molecule 
compounds (Kay et al., 1998). 
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GELATINASES AND OTHER MATRIX METALLOPROTEINASES 
 
The gelatinases A and B, also known as matrix metalloproteinase-2 and -9 or type IV 
collagenases are members of the matrix metalloproteinase family. The matrix 
metalloproteinases are a group of zinc-dependent metalloenzymes containing about 25 
members in vertebrates. These enzymes participate in the turnover of extracellular matrix 
(ECM) and together the MMPs are able to degrade any of the matrix components (Sternlicht 
and Werb, 2001). The MMPs are not only involved in the mechanical removal of structural 
proteins in the extracellular matrix. They are also able to regulate multiple cellular functions 
including cell growth, apoptosis, angiogenesis, invasion, metastasis and immune response 
by cleaving growth factor-precursors, cell adhesion molecules and other bioactive proteins 
(Egeblad and Werb, 2002). Of the MMPs, a specific subset, the gelatinases (MMP-2 and 
MMP-9) have been intensively studied in cancer and other diseases. MMP-2 is abundantly 
expressed in normal fibroblasts, endothelial and epithelial cells as well as in many 
transformed cells (Giannelli et al., 1997; Hipps et al., 1991; Partridge et al., 1997; Vartio 
and Vaheri, 1981). MMP-9 expression is observed in normal leukocytes as well as in 
transformed cells (Murphy et al., 1980; Sopata and Wize, 1979; Vartio et al., 1982). The 
genes encoding the gelatinases have been cloned (Huhtala et al., 1990; Huhtala et al., 1991) 
and these enzymes can be purified with gelatin-affinity chromatography (Hibbs et al., 1985; 
Johansson and Smedsrod, 1986; Vartio and Vaheri, 1981; Vartio et al., 1982). In addition, 
gelatin zymography is a simple and highly sensitive technique, which allows relatively 
specific detection of the gelatinases and their activation status in biological samples (Hibbs 
et al., 1985). This property has significantly aided in linking the gelatinases into various 
biological processes. MMP-2 and MMP-9 are highly similar enzymes in many respects, but 
significant differences exist in the regulation of expression, glycosylation, proenzyme 
activation and substrate selectivity. For example, MMP-2 is a 72-kDa nonglycosylated 
protein, whereas the 92-kDa MMP-9 contains two N-glycosylated sites in the prodomain 
and the catalytic domain (Kotra et al., 2002) and a number of O-linked glycans (Mattu et 
al., 2000; Rudd et al., 1999). Furthermore, MMP-9 exists in plasma as a monomer, 
complexed with neutrophil lipocalin and as a dimer, whereas MMP-2 is strictly monomeric. 
Despite their largely overlapping functions, MMP-2 and MMP-9 may even have opposing 
biological activity as illustrated by the finding that MMP-2 promotes platelet aggregation, 
but MMP-9 inhibits the same process (Fernandez-Patron et al., 1999). 
 
Physiological and pathological roles of gelatinases 
 
Gelatinases play a role in a wide variety of physiological and pathological conditions, 
among which their role in cancer has been the most extensively studied. The gelatinases are 
required in invasive prosesses during reproduction, growth and development, leukocyte 
mobilization and inflammation, and wound healing. Increased gelatinase activity has been 
observed in a variety of pathological conditions including cancer, inflammation, infective 
diseases, degenerative diseases of the brain and vascular diseases (Van den Steen et al., 
2002). 
  
During reproduction the cells of the implanting embryo secrete gelatinases and other MMPs 
(Alexander et al., 1996; Behrendtsen et al., 1992). Consequently in some MMP-9 knockout 
mice strains a reduced breeding efficiency has been observed (Dubois et al., 2000). 
Although MMPs are widely expressed in the developing embryos, all single MMP knockout 
animals generated so far are viable, with only minor developmental defects. The MMP-9 
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deficient mice show a delayed vascularization and ossification of the hypertrophic zones in 
cartilage resulting in moderate skeletal abnormalities. This phenotype is similar, athough 
less severe than the phenotype of the membrane type (MT)1-MMP knockout mice 
(Holmbeck et al., 1999; Vu et al., 1998). Despite the high level expression of MMP-9 in 
leukocytes, no major immunodeficiences have been observed in MMP-9 deficient mice 
(Van den Steen et al., 2002). However, young MMP-9 deficient mice are resistant to 
experimental autoimmune encephalomyelitis (Dubois et al., 1999). The gelatinases are also 
implicated in cardiovascular diseases. Loss of MMP-9 gene in atherosclerosis-prone mice 
reduced the growth of atherosclerotic lesions, and protected mice from the destruction of the 
atherosclerotic media implicating that MMP-9 is intimately involved in the pathogenesis of 
atherosclerosis (Luttun et al., 2004). The phenotype of MMP-2 deficient mice is relatively 
mild with minor defects in developmental angiogenesis and in the skeleton and joints (Corry 
et al., 2002; Itoh et al., 1998). However, tumor angiogenesis and tumor growth in the MMP-
2 deficient mice is highly reduced (Itoh et al., 1998). Significantly, MMP-2/MT1-MMP 
double knockout results in death of the mice immediately after birth with respiratory failure, 
abnormal blood vessels, and immature muscle fibers (Oh et al., 2004). In contrast, MMP-
2/MMP-9 knockout mice are viable (Baluk et al., 2004; Corry et al., 2004). These gelatinase 
double-knockout mice have been tested in a mycoplasma infection model in the airways. 
These gelatinase-deficient mice did not differ from their wild type littermates in the 
inflammatory response, except for that they could not induce gelatinase expression. The 
gelatinase-deficiency did not affect leukocyte influx into the airway lumen and lung 
mucosa, neither was the infection-associated microvascular remodelling affected by the lack 
of gelatinases (Baluk et al., 2004). However, in another inflammation model, although the 
accumulation of inflammatory cells in the lungs was not affected, a decreased number of 
inflammatory cells was found in the airway lumen of the MMP-9 and the double knockout 
mice due to a defect in the transepithelial chemokine gradient formation (Corry et al., 2004). 
It will be interesting to see the effect of the double knockout on tumor development and 
metastasis. 
 
The gelatinases participate also in wound repair (Legrand et al., 1999; Mohan et al., 2002; 
Salonurmi et al., 2004) and are typically expressed from the beginning to the end of the 
healing process (Salo et al., 1994). Gelatinases and other MMPs are also able to participate 
in the regulation of apoptosis. MMP-9 has been observed to decrease cancer-cell apoptosis 
(Bergers et al., 2000), whereas developmental apoptosis is augmented (Vu et al., 1998). 
MMP-2, or more specifically a C-terminal naturally occurring fragment of MMP-2 can 
induce apoptosis in tumor and endothelial cells (Bello et al., 2001). In addition, mice 
deficient in MMP-2, -3 or –9 show reduced hepatocyte apoptosis in a lethal hepatitis model 
(Wielockx et al., 2001). 
 
Structural features of matrix metalloproteinases 
 
MMPs can be grouped to eight classes, based on their domain structure (Figure 2). All 
MMPs contain a N-terminal predomain that is required for the correct secretion of these 
enzymes. The predomain is followed by a prodomain. The prodomain forms an essential 
contact with the catalytic zinc ion and maintains the latency of the MMPs (see below). The 
prodomain is followed by a catalytic domain, which contains the characteristic signatures 
for zinc-dependent metalloenzymes. The catalytic center of MMPs contains a zinc-binding 
HEBXHXBGBXHS motif, where H is histidine, E is glutamic acid, B is a bulky 
hydrophobic amino acid, G is glycine, X is variable amino acid and S is serine. The serine 
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can also be replaced by a threonine in a few MMPs, such as MMP-11 (Stocker et al., 1995). 
There is also an absolutely conserved methionine residue located on the opposite site of the 
zinc ion as compared to the HEBXHXBGBXHS motif. However, the role of this conserved 
methionine is unclear as serine or leucine mutants of this residue in MMP-2 show identical 
proteolytic activity towards various substrates (Butler et al., 2004). All MMPs except MMP-
7, MMP-23 and MMP-26 contain a hemopexin/vitronectin–like domain (Gomis-Ruth, 
2004), which is linked to the catalytic domain by a short linker or a hinge region. The role 
of the hinge region in MMPs is unclear, although it has been reported that mutations in the 
MMP-8 hinge region affect autoproteolysis and substrate specificity (Knauper et al., 1997). 
MMP-9 has additionally a unique collagen V-like insertion between the catalytic domain 
and the C-terminal domain. The function of this insertion is unknown, but it contains most 
of the O-linked glycans of MMP-9 (Mattu et al., 2000; Rudd et al., 1999). The 
hemopexin/vitronectin-like C-terminal domain is responsible for multiple protein-protein 
interactions. It binds tissue inhibitors of matrix metalloproteinases (TIMPs), certain MMP 
substrates and is involved in the activation of some MMPs. The hemopexin-like domain 
also participates in the homodimerization of MMP-9 (Cha et al., 2002) and MT1-MMP 
(Lehti et al., 2002). Also heterodimers of MMP-9 and MMP-1 can form through the C-
terminal domain interactions (Goldberg et al., 1992). Whereas MMP-7 and MMP-26 lack 
the hemopexin -like domain completely, MMP-23 has a cysteine- and proline-rich 
interleukin-1 type II receptor -like domain instead of a hemopexin-like domain. 
Furthermore, MMP-23 is bound to the cell surface through a unique N-terminal signal 
anchor (Pei et al., 2000). 
 
Figure 2. Domain 
structure of MMPs. Pre, 
signal sequence; Pro, 
propeptide with the 
cysteine switch 
sequence; Zn, zinc-ion 
binding site with the 
consensus sequence 
indicated; CBD, 
collagen/gelatin binding 
domain; F, furin-
cleavage site; TM, 
transmembrane domain; 
Cyto, cytoplasmic 
domain; Vn, vitronectin-
like insertion; IL-1R-like, 
interleukin-1 receptor 
like domain. Modified 
from Sternlicht and 
Werb (2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 20
Other extra domains that are not common to all members of MMPs include the collagen-
binding domain (CBD) of gelatinases and the transmembrane domains of MT-MMPs. The 
CBD domain is composed of three fibronectin type II like repeats and is involved in binding 
of collagenous substrates and elastin (Steffensen et al., 1995), fatty acids (Berton et al., 
2001) and thrombospondins (Bein and Simons, 2000). Although most of the MMPs are 
secreted proteins, six of them contain a transmembrane domain that is used to anchor these 
proteins on the cell surface. These MT-MMPs have a single pass transmembrane domain 
and a short cytoplasmic domain (MMP-14, -15, -16 and -24) or a glycophosphatidyl inositol 
(GPI) insertion signal (MMP-17 and –25). 
 
The first complete MMP structure to be solved was that of proMMP-2 (Figure 3) 
(Morgunova et al., 1999). The proMMP-2 has also been crystallized with the tissue inhibitor 
of matrix metalloproteinase (TIMP)-2 (Morgunova et al., 2002). The structures of many 
other MMP domains have been solved and these provide a scaffold for the development of 
MMP-binding small molecules. For example, three different partial structures of MMP-9 
with the level of 2.5 Å resolution or better have been published. One is a C-terminally 
deleted proMMP-9 construct lacking the collagen V-like region and the hemopexin-like 
domain (Elkins et al., 2002). A catalytic domain of MMP-9 lacking the collagen-binding 
domain has been crystallized in the presence of a hydroxamate inhibitor (Rowsell et al., 
2002). The C-terminal domain is the third resolved MMP-9 structure and this structure 
reveals the mechanism of MMP-9 dimerization (Cha et al., 2002). Together, these structures 
span the whole proMMP-9 except for the collagen V-like region. 
 
 
Figure 3. Structure of proMMP-2. The 
different domains as well as the individual 
fibronectin type II (FnII) repeats are shown. 
ProMMP-9 differs from proMMP-2 primarily by 
having the collagen V–like hinge region 
between the catalytic domain the C-terminal 
hemopexin/vitronectin–like domain. The effect 
of the collagen V-like insertion to the overall 
structure of MMP-9 is not known. The 
proMMP-2 structure was generated with 
Swiss-PdbViewer v3.7 from the PDB entry 
1CK7 (Morgunova et al., 1999). 
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Gelatinase substrates 
 
Gelatinase substrates include a wide variety of proteins including ECM proteins, 
proteinases, proteinase inhibitors, blood clotting factors, chemotactic molecules, latent 
growth factors and growth factor binding proteins, cell surface receptors, adhesion 
molecules and even intracellular substrates (Table 1). However, the relevance of these 
events in vivo is unclear at present. The concensus cleavage sequences of both MMP-2 and 
MMP-9 have been mapped with the substrate phage (Chen et al., 2002; Kridel et al., 2001). 
The substrate specificities of MMP-2 and MMP-9 are similar but not identical. The most 
notable difference is the ability of MMP-2 to degrade native type I collagen. The difference 
in the substrate specificity of gelatinases has been attributed to the S2 subsite in the catalytic 
site, where MMP-9 contains an aspartic acid, and MMP-2 a glutamic acid (Chen et al., 
2003). The catalytic domains of MMP-2 and MMP-9 also differ in their S1' binding pockets 
(Elkins et al., 2002; Rowsell et al., 2002). These minor differences in the catalytic domain 
have functional consequences in the substrate selectivity of the gelatinases. The amino acid 
residue fitting to the S2 subsite in the gelatinase substrates appears to be a major selectivity 
determinant based on the cleavage sequences obtained with the substrate-phage (Table 2). 
Indeed, some substrates show over 200-fold selectivity towards MMP-2 (Chen et al., 2002; 
Kridel et al., 2001). 
 
 
 
Table 1. Gelatinase substrates 
Matrix substrates MMP-2 MMP-9 Reference 
Denatured collagens (gelatins) yes yes (Morodomi et al., 1992; Okada et al., 1990) 
Native collagen type: I yes no (Aimes and Quigley, 1995) 
                                  III yes no (Berton et al., 2000) 
                                  IV yes yes (Morodomi et al., 1992) 
                                  V yes yes (Morodomi et al., 1992) 
                                  VII yes (Seltzer et al., 1989) 
                                  X yes (Cole et al., 1993) 
                                  XI yes (Smith et al., 1991) 
                                  XVIII  yes (Ferreras et al., 2000) 
Aggrecan yes yes (Fosang et al., 1992) 
BM-40/SPARC/ Osteonectin yes yes (Sasaki et al., 1997) 
Brevican yes no (Nakamura et al., 2000) 
Decorin yes no (Imai et al., 1997) 
Elastin yes yes (Murphy et al., 1991) 
Entactin/nidogen no yes (Mayer et al., 1993; Sires et al., 1993) 
Fibrillin yes yes (Ashworth et al., 1999) 
Fibrin  yes (Lelongt et al., 2001) 
Fibrinogen yes yes (Bini et al., 1996; Lelongt et al., 2001) 
Fibronectin yes no (Okada et al., 1990) 
Laminin yes yes (Giannelli et al., 1997; Morodomi et al., 
1992) 
Link protein yes yes (Nguyen et al., 1993) 
NG2 proteoglycan  yes (Larsen et al., 2003) 
Neurocan yes (Turk et al., 2001) 
Tenascin yes no (Siri et al., 1995) 
Vitronectin yes yes (Imai et al., 1995) 
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Table 1. continued  
Bioactive substrates MMP-2 MMP-9 Reference 
α1-proteinase inhibitor  yes (Liu et al., 2000) 
α2-macroglobulin yes yes (Arbelaez et al., 1997) 
αB-crystallin  yes (Starckx et al., 2003) 
Amyloid protein precursor yes  (LePage et al., 1995) 
Big endothelin-1 yes yes (Fernandez-Patron et al., 2002) 
Calcitonin gene-related peptide 
(CGRP) 
yes  (Fernandez-Patron et al., 2000) 
Complement protein C1q yes yes (Ruiz et al., 1999) 
Connective tissue-activating peptide-
III (CTAP-III) 
 yes (Van den Steen et al., 2000) 
Eph B1 tyrosine kinase receptor yes no (Chen et al., 2002) 
Epithelial-cell derived neutrophil 
activating peptide-78/CXCL5 (ENA-
78) 
 yes (Van Den Steen et al., 2003) 
Fibroblast growth factor receptor 
(FGFR) –1 
yes no (Levi et al., 1996) 
Galectin-3 yes yes (Ochieng et al., 1994) 
Granulocyte 
chemotactic protein-2 
/CXCL6 (GCP-2) 
 yes (Van Den Steen et al., 2003) 
Growth-regulated oncogene (GRO)-α yes (Van den Steen et al., 2000) 
Insulin yes (Descamps et al., 2003) 
Insulin-like growth factor binding 
proteins (IGFBP) 
yes yes (Fowlkes et al., 1994; Manes et al., 1999; 
Thrailkill et al., 1995) 
Intercellular adhesion 
molecule (ICAM)-1 
 yes (Fiore et al., 2002) 
Interferon (IFN)-β   yes (Nelissen et al., 2003) 
Interferon-inducible protein-10 (IP-
10/CXCL-10) 
 yes (Van den Steen et al., 2003) 
Interleukin receptor IL-2Rα no yes (Sheu et al., 2001) 
KiSS-1 protein/metastin yes yes (Takino et al., 2003) 
Kit-ligand  yes (Heissig et al., 2002) 
Monocyte chemoattractant protein 
MCP-3 
yes no (McQuibban et al., 2002) 
Monokine induced by interferon IFN-γ 
(MIG/CXCL-9)  
                   yes (Van den Steen et al., 2003) 
Myelin basic protein yes yes (Chandler et al., 1995) 
Myosin heavy chain yes yes (Rouet-Benzineb et al., 1999) 
Plasminogen yes yes (O'Reilly et al., 1999; Patterson and Sang, 
1997) 
Platelet factor (PF)-4 yes (Van den Steen et al., 2000) 
Poly (ADP-ribose) polymerase (PARP) yes  (Kwan et al., 2004) 
Pregnancy zone protein yes yes (Arbelaez et al., 1997) 
Pro-IL-1β yes yes (Schonbeck et al., 1998) 
Pro-IL-8 yes (Van den Steen et al., 2000) 
MMP-1 (trypsin-activated) yes (Crabbe et al., 1994) 
Pro-MMP-2 yes (Crabbe et al., 1993) 
Pro-MMP-9 yes yes (Fridman et al., 1995; Ray et al., 2003) 
Pro-MMP-13 yes (Knauper et al., 1996) 
Pro-TGF-β1 yes yes (Yu and Stamenkovic, 2000) 
Pro-TNF-α yes yes (Gearing et al., 1994) 
Pro-urokinase yes (Prager et al., 2003) 
Stromal cell derived factor (SDF)-1 yes yes (McQuibban et al., 2001) 
Substance P  yes (Backstrom and Tokes, 1995) 
Troponin yes (Wang et al., 2002) 
Urokinase receptor yes no (Andolfo et al., 2002) 
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Gelatinase binding to native collagens and gelatin occurs primarily via the CBD (Allan et 
al., 1995), whereas other MMPs, eg. MMP-3 utilizes the C-terminal domain for collagen 
binding (Allan et al., 1991). However, gelatin binds also to the C-terminal domain of the 
gelatinases (Collier et al., 2001; Roeb et al., 2002). It has been shown that binding of type I 
collagen to the C-terminal domain and the catalytic domain of MMP-2 is sufficient for 
collagenolysis, whereas subsequent gelatinolysis requires the participation of the CBD 
(Patterson et al., 2001). The C-terminal domain of gelatinases may also bind non-
collagenous substrates (McQuibban et al., 2000). The residues contributing to the gelatin 
binding in the CBD have been identified by site-directed mutagenesis, and are located in the 
second fibronectin type II module of both gelatinases (Collier et al., 1992; Tordai and 
Patthy, 1999). These gelatin binding residues in MMP-2 have been thoroughly examined by 
NMR using gelatin-mimicking (proline-proline-glycine)n peptides (Briknarova et al., 2001; 
Briknarova et al., 1999; Gehrmann et al., 2002). Peptides binding to the recombinant CBD 
and the individual fibronectin type repeats of MMP-2 have been isolated using phage 
display, but they do not show any significant similarity to sequences found in collagens or 
other potential substrates (Trexler et al., 2003). 
 
The three fibronectin type II repeats form a three-pronged fishhook -like structure in 
proMMP-2 (Morgunova et al., 1999), and this conformation may be needed for the 
unwinding and complete degradation of the triple helical collagens (Overall, 2002). In the 
proMMP-2 structure, the prodomain peptide PIIKFPGDVA interacts intramolecularly with 
the putative gelatin-binding site of the third fibronectin type II repeat via contacts that 
involve propeptide amino acid residues Ile35, Phe37, and Asp40 (Morgunova et al., 1999). 
This binding may represent an additional mechanism in maintaining the latency of the 
progelatinases. It is also of interest to note that the relative affinities of the substrates to the 
gelatinases may vary depending on the activation status of the enzyme. ProMMP-9 binds 
type I collagen with a higher affinity than active MMP-9, whereas the opposite is true for 
type IV collagen recognition (Allan et al., 1995). The biological significance of these 
differences in the affinities is unclear at present. 
 
Table 2. The consensus cleavage sites of the gelatinases 
 Consensus  Example   Selectivity   
 cleavage sitea peptide vs.MMP-9 vs.MMP-7 vs.MMP-13 
MMP-2, group I  PXX’XHy AKPRA’LTA 2 21 14 
                       II I/LXX’XHy LRLA’AITA 14 6 13 
                       III XHySX’L NRYSS’LTA 40 84 24 
                       IV HXX’XHy HMHAA’LTA 100 n.d. n.d. 
MMP-9, group I PR(S/T)’XHy(S/T) KGPRQ’ITA n.a. 14 12 
                      II XXG’L(K/R)X GSG’LKA n.a. 1 0.3 
                       III XRR’XHy(I/L)X GRR’LLSR n.a. n.d. n.d. 
 aXHy hydrophobic amino acid; n.a. not applicable; n.d. not determined. Data from (Chen et al., 2002;    
 Kridel et al., 2001). 
 
Regulation of MMP activity 
 
In order to avoid unwanted tissue damage it is crucial to accurately control the protease 
activity. For this reason, protease activity is typically regulated at multiple levels including 
transcription, secretion, activation, and by the action of proteinase inhibitors. MMPs 
including the gelatinases are no exception in this respect. 
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Expression and secretion of gelatinases and other MMPs 
 
A major difference between MMP-2 and MMP-9 is their differential regulation of 
expression (Huhtala et al., 1991). Typically, MMP-2 is rather constitutively expressed with 
only modest up or downregulation under various conditions (Birkedal-Hansen et al., 1993). 
Instead, MMP-9 expression is highly inducible and under the control of growth factors, 
chemokines and other stimulatory signals (Hipps et al., 1991). These differences can be 
traced to the promoter elements of the gelatinases (Sato and Seiki, 1993; Van den Steen et 
al., 2002; Westermarck and Kähäri, 1999). The promoter of MMP-9 is similar to most other 
MMPs, whereas MMP-2 promoter lacks many of the inducible promoter elements such as 
binding sites for the AP-1 and ETS transcription factors (Westermarck and Kähäri, 1999). 
The differential regulation of MMP-2 and MMP-9 expression is evident in cells treated with 
protein kinase C activators such as phorbol esters. Whereas the expression of MMP-9 is 
stimulated several fold, MMP-2 expression is slightly downregulated (Huhtala et al., 1991). 
Cytokines and growth factors that activate MMP-9 expression typically act via the mitogen-
activated protein kinase (MAPK) pathway, which includes the ERK 1/2, JNK/SAPK 1/2 
and p38 proteins (Westermarck and Kahari, 1999). These inducers include epidermal-
growth factor (EGF), platelet-derived growth factor (PDGF), hepatocyte growth 
factor/scatter factor (HGF/SF), basic fibroblast growth factor (bFGF), transforming growth 
factor (TGF)-α and β, amphiregulin, tumor necrosis factor (TNF)-α, interleukin (IL)-1α and 
β, interferon (IFN)-α and γ (Van den Steen et al., 2002). Due to the highly inducible nature 
of MMP-9 by growth factors and cytokines, MMP-9 promoter activity can be detected in all 
invasive tumors in mice carrying a β-galactosidase gene under the control of MMP-9 
promoter (Kupferman et al., 2000). 
 
MMP-1, -2, -3 and MT1-MMP, but not MMP-9 expression, can also be stimulated by the 
extracellular matrix metalloproteinase inducer (EMMPRIN) (Caudroy et al., 2002). 
EMMRPIN is a cell surface glycoprotein belonging to the immunoglobulin superfamily. In 
addition to the MMP expression stimulating activity, EMMPRIN acts as a cell surface 
receptor for MMP-1 (Guo et al., 2000). Other proteins that are able to regulate the activity 
of MMPs include the three small integrin-binding ligand N-linked glycoproteins 
(SIBLINGs); bone sialoprotein, osteopontin and dentin matrix protein-1. Bone sialoprotein 
specifically binds MMP-2, while osteopontin binds MMP-3, and dentin matrix protein-1 
binds MMP-9. Interestingly, binding of the SIBLINGS to the MMPs activates the 
proenzymes and reduces their susceptibility to the MMP-inhibitors (Fedarko et al., 2004). 
 
Besides the growth factor and chemokine-induced signals, integrin and extracellular matrix 
-mediated signals regulate the expression of the gelatinases and other MMPs. It was initially 
observed that antibodies blocking α5β1 integrin-mediated adhesion induced MMP expression 
in fibroblasts (Werb et al., 1989). Later studies revealed that integrin-mediated signals are 
general regulators of MMP expression, as α2β1 integrin regulates MMP-1 expression 
(Riikonen et al., 1995; Dumin et al., 2001), antibodies to α3β1 integrin-tetraspanin 
complexes induce MMP-2 expression (Sugiura and Berditchevski, 1999), and αMβ2 and α3β1 
integrin ligation stimulates MMP-9 expression (Wize et al., 1998; Larjava et al., 1993). The 
effects on MMP expression are very specific. For example, α4β1 integrin ligation by vascular 
cell adhesion molecule-1 in T cells induces only MMP-2 and not MMP-9, but ligation of the 
same integrin to a fibronectin-derived CS-1 peptide stimulates the expression of both 
gelatinases (Yakubenko et al., 2000). Although speculative, it seems that the integrin-matrix 
interactions induce selective expression of those MMPs that are the most suitable for the 
modification of the underlying matrix.  
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Leukocytes, which have to rapidly adhere to the blood vessel endothelium and extravasate 
into tissues, have developed an additional mechanism to control gelatinase activity. These 
cells have large amounts of protease-containing granules, which are rapidly delivered to the 
cell surface and excreted to the extracellular space after leukocyte activation. Due to a high 
MMP-9 content, one of these granule types is called as gelatinase granules (Borregaard, 
1997; Cowland and Borregaard, 1999). Adherent cell types do not contain storage granules 
of gelatinases and are dependent on direct secretion of the newly synthesized enzymes. In 
endothelial and tumor cells, the gelatinases are secreted in specific transport vesicles 
containing also other proteins such as integrins and components of the plasminogen 
activation system (Dolo et al., 1999; Ginestra et al., 1997; Taraboletti et al., 2002). Integrins 
appear to be required for the delivery of these vesicles. For example, MMP-9 was not 
secreted into the cell culture medium of keratinocytes in the absence of α3β1 (DiPersio et al., 
2000). Similarly, antisense expression of αV integrin reduced MMP-9 expression in Epstein-
Barr virus infected B lymphocytes (Huang et al., 2000) and expression of αVβ6 in colon 
carcinoma increased secreted MMP-9 (Agrez et al., 1999; Niu et al., 1998). Also urokinase-
plasminogen activator receptor (uPAR) regulates MMP-9 secretion. Antisense expression of 
uPAR abrogates MMP-9 expression, but not MMP-2 or integrin expression (Aguirre Ghiso 
et al., 1999; Ahmed et al., 2003). An inverse correlation of integrin expression and MMP 
expression has been observed in HT1080 fibrosarcoma cells where overexpression of MT1-
MMP significantly reduced and antisense expression increased αVβ3 integrin expression 
(Monea et al., 2002). 
 
Proenzyme activation 
 
The gelatinases are secreted as proenzymes, and they need to be activated for full catalytic 
activity. The activation of the gelatinases and other soluble MMPs occurs on the cell surface 
or in the extracellular milieu, whereas MT-MMPs may also be activated intracellularly by 
furin-like proprotein convertases (Sato et al., 1996; Yana and Weiss, 2000; Zucker et al., 
2003). In general, proteases can be activated via multiple mechanisms and commonly a 
reciprocal activation pattern is observed, i.e., an activated protease can activate the zymogen 
of its activator (Ellis, 2003). Hence, it is highly difficult to define the initiator protease of 
the activation cascades and also how the first enzyme in the cascade is activated. One 
possibility is that some of the proenzymes are sufficiently active for the initial cleavage. 
 
The MMPs become catalytically active when the propeptide of an MMP is cleaved or the 
conformation of the propeptide is disrupted. The “cysteine switch” principle is essential for 
understanding the MMP activation process (Figure 4). MMPs contain a conserved peptide 
sequence PRCGXPD in the prodomain. The cysteine residue coordinates with the catalytic 
zinc ion and blocks the entry of a catalytically essential water molecule to the active site 
(Van Wart and Birkedal-Hansen, 1990). The various activation mechanisms of MMPs all 
disrupt the interaction of the critical cysteine with the catalytic zinc atom either by removing 
the prodomain or by modifying the cysteine residue in the prodomain. This allows the 
entrance of a water molecule in the catalytic site and results in the formation of an active 
catalytic centre. The cysteine switch mechanism explains why proteases, conformational 
perturbants such as heat, denaturants or substrate binding, heavy metals and 
organomercurials, oxidants and alkylating agents are able to activate MMPs (Van Wart and 
Birkedal-Hansen, 1990; Visse and Nagase, 2003). 
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Figure 4. The architecture of the catalytic site of 
MMPs. The thiol group from the cysteine side chain in 
the conserved PRCGXPD sequence present in the 
propeptide coordinates with the catalytic zinc ion in 
the latent MMPs. During MMP activation a water 
molecule replaces the thiol group resulting in a 
catalytically active enzyme.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The main activation route of MMP-2 on the cell surface is by the formation of a molecular 
complex containing MMP-2, MT1-MMP and TIMP-2 (Murphy and Crabbe, 1995; Strongin 
et al., 1995; Lehti et al., 1998). The N-terminal domain of TIMP-2 binds to and inhibits 
MT1-MMP, whereas the C-terminal domain of the same TIMP-2 molecule binds the 
hemopexin-like domain of MMP-2 forming a ternary complex. An adjacent TIMP-free 
MT1-MMP subsequently cleaves the MMP-2 to the intermediate 64-kDa form by cleaving 
the Asn37-Leu38 bond located in a readily accessible bait region between the first and the 
second α helix of the prodomain. This intermediate form is then processed to the fully 
mature 62-kDa form through cleavage of the Asn80-Tyr81 bond by an already active MMP-2 
molecule (Murphy and Crabbe, 1995; Strongin et al., 1995). Only the active MT1-MMP 
binds MMP-2 on the cell surface, thus regulation of MT1-MMP activation is an important 
control point to regulate MMP-2 activity (Lehti et al., 1998). Although TIMP-2 is normally 
required for the MMP-2 activation, higher TIMP-2 levels lead to inhibition of MMP-2 
activation. On the other hand, soluble MT1-MMP activates MMP-2 with a high efficiency 
in the absence of TIMP-2 (Pei and Weiss, 1996). Integrins are also involved in the 
activation process directly or indirectly as αVβ3 and β1 integrin activating antibodies 
modulate MMP-2 activation (Yan et al., 2000). The direct involvement is supported by the 
finding that the intermediate active MMP-2 is capable of αVβ3 integrin binding, and this 
interaction could thus affect MMP-2 activation (Brooks et al., 1996; Deryugina et al., 
2001). Alternatively, integrin-mediated signals may lead to the increase in MT1-MMP 
expression and activity and thus contribute to the MMP-2 activation. Endothelial cells 
cultured in a three-dimensional (3D)-collagen type I matrix express MT1-MMP with 
concomitant activation of MMP-2 whereas only a minor fraction of MMP-2 is activated in a 
2D-collagen culture (Haas et al., 1998). In addition, HT1080 cells cultured on fibronectin, 
but not on laminin-1 show increased activation of MMP-2. The activation involves integrin 
activity as immobilized antibodies to the fibronectin receptor α5β1 similarly induce MMP-2 
activation (Stanton et al., 1998). 
 
MMP-2 can also be activated by MMP-1 and MMP-7, and the activated anti-coagulant 
protein C (Nguyen et al., 2000; Sang et al., 1996), but not with MMP-3, trypsin, 
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chymotrypsin, plasmin, plasma kallikrein, thrombin, neutrophil elastase, cathepsin G or 
thermolysin (Okada et al., 1990). However, proteases that do not directly activate MMP-2 
can do so by activating MT1-MMP (Shamamian et al., 2000). Cell surface activation of 
MMP-2 can also occur through a plasminogen-mediated mechanism, which requires the 
presence of MT1-MMP, but not MT1-MMP activity (Monea et al., 2002). MMP-2 
activation can also be induced with the lectin concanavalin A (Overall and Sodek, 1990). 
The effect is likely mediated by inhibition of MT1-MMP endocytosis from the cell surface 
(Jiang et al., 2001). Intracellular activation of MMP-2 has also been observed, but the 
mechanism has not been elucidated (Lee et al., 1997).  
 
The physiological activation mechanism(s) of MMP-9 still remain(s) poorly understood. 
Plasminogen/MMP-3 mediated activation (Ramos-DeSimone et al., 1999) and activation by 
trypsin-2 (Sorsa et al., 1997) appear to be the most potent activators of MMP-9. 
Plasminogen/MMP-3 mediated activation involves activation of plasminogen to plasmin by 
urokinase plasminogen activator (uPA). uPA is bound to its cell surface receptor uPAR and 
cleaves plasminogen. Plasmin is an efficient activator of proMMP-3, which then activates 
MMP-9 by sequential cleavage of the Glu40-Met41 and Arg87-Phe88 bonds (Murphy and 
Crabbe, 1995). In vivo, MMP-3 deficiency does not impair MMP-9 activation (Lijnen et al., 
1998), however other MMPs may complement MMP-9 activation in these mice. MMP-9 
can also be directly activated by plasmin but this is a relatively inefficient process. 
However, the plasmin-mediated activation is potentiated on the cell surface (Mazzieri et al., 
1997). Plasmin clearly contributes to in vivo activation of MMP-9 as the uPA-deficient mice 
show reduced activation of MMP-9, as well as that of MMP-3, -12 and –13 (Carmeliet et 
al., 1997). In vitro, MMP-9 can also be activated using MMP-2 (Fridman et al., 1995), 
MMP-3 (Ogata et al., 1992), MMP-7 (von Bredow et al., 1998), MMP-10 (Nakamura et al., 
1998), MMP-13 (Knauper et al., 1997) and MMP-26 (Zhao et al., 2003), which all yield the 
fully active 82 kDa MMP-9. 
 
The human tumor-associated trypsin-2 is an efficient activator of MMP-9 (Sorsa et al., 
1997). MMP-9 could be activated at a 1:1000 trypsin to proMMP-9 ratio. Similarly to the 
MMP-3 mediated activation, the propeptide of MMP-9 was completely removed by 
cleavage of the Arg87-Phe88 bond (Sorsa et al., 1997). Recently, it was reported that MMP-9 
can be activated by MT1-MMP/MMP-2 and MMP-3 on the cell membranes more 
efficiently than in solution (Toth et al., 2003). Chymotrypsin-like proteinase in human skin 
(Han et al., 2002) and mast cell derived α and β chymase (Coussens et al., 1999; Fang et al., 
1997) have also been reported to activate MMP-9. More complexity comes from the finding 
that the proMMP-9 displays significant catalytic activity in the presence of the propeptide 
(Bannikov et al., 2002). Substrate binding appears thus to be sufficient to trigger the 
cysteine switch and provides one possible solution to the dilemma that active MMP-9 is 
often not found in the tissues despite the catalytic activity of MMP-9. Neutrophils are also 
able to activate MMP-9 via an oxidative mechanism (Peppin and Weiss, 1986). 
Additionally, it has been observed that MMP-9 can be activated by S-nitrosylation (Gu et 
al., 2002). Both gelatinases can be activated via free radical-generating 2- and 4-
hydroxyestradiols (Paquette et al., 2003). Organomercurials such as aminophenylmercuric 
acetate (APMA) are commonly used as MMP activators. With APMA, the propeptide of 
MMP-9 is not completely removed. Furthermore, a prolonged incubation with APMA 
results in the autolytic processing of the C-terminal domain with three successive cleavages 
(Triebel et al., 1992). 
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GELATINASE INHIBITORS   
Naturally occuring gelatinase inhibitors 
 
Both naturally occurring and synthetic MMP inhibitors have been identified and 
characterized. Some of them show significant selectivity towards the gelatinases (Table 3). 
The physiological inhibitors of gelatinases include α2-macroglobulin and the tissue 
inhibitors of MMPs (TIMPs). α2-macroglobulin is an abundant plasma protein and 
effectively inhibits the activity of most proteinases, including the MMPs (Sottrup-Jensen 
and Birkedal-Hansen, 1989). Binding to α2-macroglobulin is an efficient indicator of MMP 
activation status as only the activated enzymes bind it (Morodomi et al., 1992). The α2-
macroglobulin may play an important role in the endocytic removal of proteolytic enzymes 
(Moestrup et al., 1993). The inhibitor-MMP complexes are internalized into cells via the 
low-density lipoprotein receptor-related protein (LRP) and are eventually degraded. 
However, MMP-9 can also be internalized as a monomer or TIMP-1 complex and MMP-2 
with thrombospondin-2 apparently in the absence of α2-macroglobulin (Hahn-Dantona et 
al., 2001; Yang et al., 2001). 
  
TIMPs are relatively small, cysteine rich proteins. They form high-affinity 1:1 complexes 
with the MMPs. TIMPs-1, 2, 3 and 4 vary in tissue specific expression and their ability to 
inhibit various MMPs (Egeblad and Werb, 2002). For example, TIMP-1 inhibits MMP-9 
with a high affinity, whereas TIMP-2 inhibits MMP-2 (O'Connell et al., 1994; Olson et al., 
1997). TIMPs also inhibit the activity of other metalloproteinases, namely members of the 
ADAM (a disintegrin and metalloproteinase) family (Amour et al., 2000; Amour et al., 
1998; Egeblad and Werb, 2002). Studies with TIMP-2 knockout mice indicate that the 
dominant function of TIMP-2 in vivo is the activation of proMMP-2 (Wang et al., 2000).  
The crystal structure of proMMP-2 with TIMP-2 reveals the structural basis for this 
interaction required for MMP-2 activation. The C-terminal hemopexin-like domain of 
MMP-2 interacts with the C-terminal domain of TIMP-2, whereas the catalytic domain of 
MMP-2 and the MMP inhibitory N-terminal domain of TIMP do not form contacts in this 
structure (Morgunova et al., 2002). The MMP-2/TIMP-2 complex also reveals why TIMP-1 
does not interact with MMP-2. This is because TIMP-1 lacks the critical C-terminal MMP-2 
interacting residues present in TIMP-2 (Morgunova et al., 2002). Despite the MMP-
inhibitory activity of TIMPs, several studies have showed that a high level of TIMP-1 or –2 
correlate with a poor prognosis in many types of cancer (Fong et al., 1996; Murashige et al., 
1996; Ree et al., 1997; Yoshizaki et al., 2001). It is not known, whether this is due to an 
attempt to compensate for the increased MMP levels or an independent cause as TIMPs do 
have other functions independent on MMP inhibition. Under some conditions, the TIMPs 
can inhibit tumor-cell apoptosis as well as promote cell growth and angiogenesis. For 
example, TIMP-4 can upregulate an anti-apoptotic protein Bcl-XL and stimulate mammary 
tumorigenesis (Jiang et al., 2001). The growth promoting activities of TIMPs are not well 
understood, but are observed in many cell types and appear to be independent of MMP-
inhibitory activity (Nemeth et al., 1996). TIMPs have also MMP-independent cancer-
inhibiting functions. TIMP-2 may directly inhibit endothelial cell proliferation and 
angiogenesis by acting through α3β1 integrin and causing a decrease in tyrosine phosphatase 
activity associated with this integrin (Seo et al., 2003). TIMP-3 can directly inhibit 
angiogenesis through blockage of VEGF binding to the VEGF receptor-2 (Qi et al., 2003). 
An interesting observation is that TIMP-1, in addition to the extracellular milieu, can also be 
found in the nucleus (Zhao et al., 1998), and may even be specifically translocated there 
from the cell membrane (Ritter et al., 1999). Recently, also MMP-2 was found to be present 
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in the nucleus, and a pro-apoptotic nuclear protein, poly (ADP-ribose) polymerase was 
cleaved by MMP-2 in vitro suggesting that MMP-2 could partially substitute for caspases in 
the apoptotic cascade (Kwan et al., 2004). 
 
Table 3. Inhibitors and negative regulators of gelatinases 
Inhibitor Mechanism of 
action 
Other targetsa Reference 
TIMP-1 catalytic activity Most MMPs, ADAM-10, ADAMTS-
4 
(Egeblad and Werb, 2002) 
TIMP-2 catalytic activity Most MMPs, ADAMTS-4 (Egeblad and Werb, 2002) 
TIMP-3 catalytic activity Most MMPs, ADAM-10, -12, -17, 
ADAMTS-4, -5 
(Egeblad and Werb, 2002) 
TIMP-4 catalytic activity most MMPs, ADAMTS-4 (partly) (Egeblad and Werb, 2002) 
α2-macroglobulin catalytic activity, 
clearance 
most proteases (Morodomi et al., 1992) 
Procollagen C-
terminal proteinase 
enhancer (PCPE) 
catalytic activity  (Mott et al., 2000) 
Tissue factor 
pathway inhibitor-2 
catalytic activity, 
activation 
serine proteases, other MMPs (Herman et al., 2001) 
Endostatin inhibition of 
activation, catalytic 
activity 
MT1-MMP (Kim et al., 2000) 
RECK catalytic activity MT1-MMP (Takahashi et al., 1998) 
Thrombospondins inhibition of 
activation 
 (Rodriguez-Manzaneque et 
al., 2001) 
Neovastat catalytic activity VEGF, induction of endothelial cell 
apoptosis 
(Dupont et al., 1998) 
Matlystatin catalytic activity  (Tanzawa et al., 1992) 
Aspirin reduction of 
expression 
Cyclooxygenases (Jiang et al., 2001) 
Epigallocatechin-3-
gallate 
inhibition of 
activation, catalytic 
activity, reduction of 
expression 
MMP-1, -12, -13 MT1-MMP,67-
kDa laminin receptor 
(Demeule et al., 2000) 
Long chain fatty 
acids 
catalytic activity 
(exosite inhibition) 
neutrophil elastase, plasmin  (Berton et al., 2001) 
Prinomastat AG3340, 
(non-peptidomimetic 
hydroxamate) 
catalytic activity MT1-MMP, MMP-13 (Shalinsky et al., 1999) 
CT1166 
(peptidomimetic) 
catalytic activity MMP-3 (Hill et al., 1995) 
Ro 28-2653 
(Pyrimidine-2,4,6-
Trione) 
catalytic activity MT1-MMP, MMP-8 (Grams et al., 2001) 
Chemically modified 
tetracyclines 
catalytic activity, 
inhibition of 
oxidative activation, 
reduction of 
expression 
MT1-MMP (Sorsa et al., 1998) 
N-sulfonylamino acid 
derivatives 
catalytic activity MT1-MMP (Tamura et al., 1998) 
Bisphosphonates catalytic activity, 
reduction of 
expression 
MMP-1, -3, -7, -8, -12, -13, and 
MT1-MMP 
(Teronen et al., 1999) 
Dithiol inhibitors catalytic activity MT1-MMP (Bernardo et al., 2002) 
Cysteine switch 
peptide  
catalytic activity MMPs (Fotouhi et al., 1994) 
CTTHWGFTLC 
peptide 
catalytic activity  (Koivunen et al., 1999) 
TSRI265 docking of MMP-2 
to αVβ3 integrin 
 (Silletti et al., 2001) 
a note that the lack of other inhibitable targets may indicate that the compound has not been tested for inhibition 
of other proteinases. 
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MMP inhibiting proteins containing domains with structural similarity to TIMPs have been 
identified. The C-terminal fragment of the progollagen C-terminal proteinase enhancer 
protein was purified from human brain tumor cells due to its MMP-inhibitory activity, but it 
is a less potent inhibitor than the TIMPs (Mott et al., 2000). The noncollagenous NC1 
domains of collagen type IV are another protein domains with structural similarities to 
TIMPs (Netzer et al., 1998). Among the NC1 domains of collagen type IV, the α3 chain 
NC1 domain is the most potent inhibitor of angiogenesis and tumor growth (Petitclerc et al., 
2000). However, the domain also contains RGD-dependent and RGD-independent 
recognition sites for αVβ3 and αVβ5 integrins and can regulate angiogenesis through integrin-
mediated signalling (Pedchenko et al., 2003). Tissue factor pathway inhibitor-2, despite 
being a serine protease inhibitor, can also inhibit MMPs, including the gelatinases (Herman 
et al., 2001). 
 
Endostatin is a collagen XVIII derived 20-kDa proteolytic fragment with anti-angiogenic 
and anti-tumor properties (O'Reilly et al., 1997). The protease responsible for the generation 
of endostatin in vivo is likely cathepsin L (Felbor et al., 2000), but also cathepsin B and 
MMPs, including MMP-3, MMP-9, MMP-12, MMP-13 and MMP-20 release endostatin in 
vitro (Ferreras et al., 2000). Endostatin acts as an inhibitor of MMP-2 activation (Kim et al., 
2000) as well that of MMP-9 and MMP-13 (Nyberg et al., 2003). It also inhibits the 
catalytic activity of MMP-2 and MT1-MMP (Kim et al., 2000). 
 
The RECK protein (reversion-inducing cysteine-rich protein with Kazal motifs) is another 
inhibitor of MMPs, and is the only known membrane-bound MMP inhibitor. RECK is a 
110-kDa glycoprotein expressed in many normal tissues, but is absent from transformed and 
tumor-derived cells (Takahashi et al., 1998). RECK-transfected HT1080 fibrosarcoma cells 
accumulated only low levels of proMMP-9 in the culture medium and purified RECK bound 
MMP-9 specifically and inhibited the enzymatic activity of MMP-9 (Takahashi et al., 
1998). RECK is also a negative regulator of MMP-2 and MT1-MMP in vivo decreasing 
angiogenesis and tumor growth. Interestingly, in contrast to MMP deficient animals, 
deletion of a functional RECK gene is lethal (Oh et al., 2001). 
 
Thrombospondin-1 (TSP-1) is an extracellular 450-kDa glycoprotein with anti-angiogenic 
properties (Qian et al., 1997). TSP-1 directly binds MMP-9 and inhibits its activation both 
in vitro and in vivo (Rodriguez-Manzaneque et al., 2001). Consequently, TSP-1-deficient 
mice show increased angiogenesis and tumor growth, which can be linked to an increased 
association of vascular endothelial growth factor with VEGFR-2 and appearance of active 
MMP-9 (Rodriguez-Manzaneque et al., 2001). Contrasting activities have also been 
reported, as TSP-1 upregulates MMP-9 expression and stimulates invasion of endothelial 
cells in vitro (Qian et al., 1997). Yeast two-hybrid assays revealed that the thrombospondin 
type 1 repeats in TSP-1 and TSP-2 interact with the collagen-binding domain of MMP-2 
and MMP-9 indicating the potential inhibition mechanism (Bein and Simons, 2000). 
 
A few naturally occuring small-molecule inhibitors of gelatinases have been identified. 
Neovastat is a shark cartilage extract with anti-angiogenic activity through inhibition of 
MMPs, although the exact nature of the active ingredient in the extract has not been 
reported (Dupont et al., 1998). Neovastat has multiple modes of action as it additionally 
inhibits many VEGF-dependent events in vivo (Falardeau et al., 2001). Matlystatins are 
produced by an actinomycete strain Actinomadura atramentaria and inhibit gelatinases with 
an IC50 value less than 1 µM (Tanzawa et al., 1992). Aspirin (acetylsalicylic acid) reduces 
MMP-9 expression and causes inhibition of Epstein-Barr virus latent membrane protein-1 
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induced invasiveness of tumor cells in vivo (Murono et al., 2000). Aspirin also suppresses 
MMP-2 production and reduces in vitro invasiveness of tumor cells (Jiang et al., 2001). 
However, aspirin does not appear to directly inhibit gelatinases. A potential mechanism for 
the inhibition is the induction of the RECK protein (Liu et al., 2002). A polyphenolic 
compound in green tea, epigallocatechin-3-gallate, is a potent inhibitor of gelatinases, but it 
is not gelatinase selective as it inhibits also other MMPs (Demeule et al., 2000). 
 
Long-chain fatty acids with 10 to 18 carbon atoms inhibit both gelatinases, but only weakly 
other MMPs as their binding site is in the collagen-binding domain (Berton et al., 2001). In 
general, the long and unsaturated fatty acids appear to be more potent than the short 
saturated ones (Berton et al., 2001). However, the long-chain fatty acids are not gelatinase 
selective gelatinase, as they also inhibit other proteinases including neutrophil elastase and 
plasmin (Ashe and Zimmerman, 1977; Higazi et al., 1994). 
 
Synthetic gelatinase inhibitors 
 
Most of the synthetic MMP inhibitors target the catalytic site of the MMPs and act by 
chelating the catalytically essential zinc ion. Due to the huge interest in the therapeutic 
intervention of MMPs in cancer, over a hundred small molecule MMP inhibitors have been 
designed and synthesized (Whittaker et al., 1999). The zinc binding groups that have been 
utilized in MMP inhibitors include carboxylates, aminocarboxylates, sulfhydryls, thiols, 
phosphoric acid derivatives and hydroxamates (Whittaker et al., 1999). From these, the 
hydroxamate-based inhibitors are the most widely used. Batimastat (BB-94) was the first 
synthetic MMP inhibitor and showed potent antitumor activity in mice (Davies et al., 1993). 
It is a non-orally bioavailable peptidomimetic hydroxamate inhibitor based on the MMP 
cleavage site in collagens (Whittaker et al., 1999). The first inhibitors were followed by 
orally bioavailable inhibitors, such as marimastat. Many non-peptidomimetic MMP 
inhibitors have also been developed and tested in clinical trials, these include the 
compounds BAY12-9566, AG3340 and BMS-275291 (Whittaker et al., 1999). Prinomastat 
(AG3340) is a rather selective gelatinase inhibitor, inhibiting MMP-1, -7 and -11 much less 
efficiently. However, it shows picomolar affinity to MT1-MMP and MMP-13 (Shalinsky et 
al., 1999). Other selective active-site inhibitors of gelatinases have also been synthesized 
(Tamura et al., 1998). These N-sulfonylamino acid derivatives are orally bioavailable and 
effectively suppress tumor growth in a mouse model, but their inhibitory profile towards 
other MMPs has not been completely elucidated (Tamura et al., 1998). Two related active 
site inhibitors with a dithiol structure have been identified as selective gelatinase inhibitors 
(Bernardo et al., 2002; Rosenblum et al., 2003). Due to the dithiol moiety in these 
chemicals, they induce a conformational change in the gelatinases, which is not easily 
reversible (Bernardo et al., 2002). 
 
It is highly difficult to synthesize specific active site inhibitors for an individual MMP. This 
is because the catalytic sites of MMPs show remarkable similarity, which is also reflected 
by the overlapping substrate specificity of the MMPs. The X-ray structures of several 
MMPs have established that the S1’ subsite in the catalytic site is the main determinant of 
the substrate specificity as well as a selectivity determinant for the inhibitors. Based on the 
S1’ subsites, MMPs can be divided into deep pocket and shallow pocket containing 
inhibitors. MMP-2, -3, -8, -9, -13 and MT1-MMP contain a deep pocket, whereas MMP-1 
and MMP-7 have a shallow S1’ pocket (Zucker et al., 2000). Other investigators further 
divide the MMPs into intermediate pocket containing enzymes, where MMP-2, -8, –9 and –
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26 are classified as intermediate ones (Park et al., 2003). Differences in other sites such as 
the S2 site can be further utilized in order to increase the selectivity of the inhibitors (Chen 
et al., 2003; Kridel et al., 2001). 
 
Tetracyclines, which in addition to their antimicrobial activity inhibit inflammatory cell 
migration and chemotaxis to sites of inflammation, act also as MMP inhibitors. The ability 
of tetracyclines to inhibit MMPs is independent of their anti-microbial activity (Sorsa et al., 
1998). The tetracyclines act on two levels, they suppress the gelatinase expression (Seftor et 
al., 1998) and directly inhibit gelatinase activity trough a zinc-chelating effect (Sorsa et al., 
1998). The tetracycline derivatives have entered clinical trials as MMP-inhibitors 
(Cianfrocca et al., 2002). Clodronate and other bisphosphonates have been developed to 
treat bone diseases due to their ability to inhibit bone resorption. However, it has been also 
found that these compounds directly inhibit MMP activity (Teronen et al., 1999). 
 
The cysteine switch peptide MRKPRCGVPDVG from the prodomain of MMP-3 was the 
first peptide used to block the enzymatic activity of the MMPs (Fotouhi et al., 1994), 
whereas the phage display-derived CTTHWGFTLC (CTT) peptide was the first gelatinase-
selective peptide inhibitor (Koivunen et al., 1999). The CTT peptide did not inhibit the 
activity of MT1-MMP, MMP-8 or MMP-13. The mechanism how CTT inhibits gelatinase 
activity is not known. The CTT peptide was enriched in a biopanning with active MMP-9 
and was the most potent inhibitor among the peptides containing a WGF motif. The CTT 
peptide inhibited the migration of several cell lines in vitro and retarded tumor progression 
in mouse models. It also exhibited a strong tumor homing ability in comparison to the 
normal tissues (Koivunen et al., 1999). The targeting capability of CTT was further 
demonstrated with liposomes coated with the CTT peptide. These liposomes efficiently 
targeted gelatinase-expressing cancer cells in vitro (Medina et al., 2001). The CTT peptide 
has also been used to modify the natural tropism of adenovirus for a therapeutic gene 
delivery in a rabbit restenosis model (Turunen et al., 2002). In addition, CTT peptide has 
been used to localize gelatinase activity in tissue samples using in situ zymography (Pirilä et 
al., 2001), and to evaluate the contribution of gelatinases in various biological processes 
including vasoconstriction, epithelial-mesenchymal transition and hepatitis (Cheng and 
Lovett, 2003; Fernandez-Patron et al., 2000; Franzke et al., 2002). 
 
There are several RNA-based strategies to inhibit the gelatinases. Ribozymes, RNA 
molecules with catalytic activity, have been utilized to inhibit translation of the gelatinases. 
Importantly, the MMP-9 down-regulated cells retained their tumorigenicity but were no 
longer able to metastasize (Hua and Muschel, 1996; Sehgal et al., 1998). MMP-2 has also 
been targeted with a ribozyme approach. MMP-2, but not MMP-9 was found to be 
necessary for glomerular mesangial cell proliferation and differentiation (Turck et al., 
1996). Similarly, adenoviral delivery of antisense mRNA of MMP-9 effectively suppressed 
tumor xenograft growth in vivo (Lakka et al., 2002). Small interfering RNAs have also been 
used to specifically silence MMP-9. Lack of MMP-9 caused a decrease in spreading of 
Ewings sarcoma cells, inhibition of chemotactic migration towards fibronectin and 
induction of E-cadherin mediated cell aggregation (Sanceau et al., 2003). Therapeutic 
inhibition of MMPs may also be achieved by other indirect means. These include targeting 
of extracellular factors, signal-transduction pathways or nuclear factors that are required for 
the transcriptional activation of MMPs. Another possibility is to inhibit the activity of the 
MMP activating proteases (reviewed by Overall and Lopez-Otin, 2002). However, those 
strategies aiming at suppressing MMP transcription may have to take into account that the 
stromal cells are often the producers of the MMPs in the tumor. 
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CELL MIGRATION AND INVASION 
 
Regulation of cell migration 
 
Cell migration is a complex process involving many types of components both intra- and 
extracellularly and the signalling events linking these. More specifically, cancer cell 
migration can be viewed as a process regulated by matrix-degrading proteinases, integrins 
and other cell adhesion molecules (Chapman, 1997). As migration is a critical event in 
cancer progression and especially metastasis, inhibition of cell migration represents an 
attractive therapeutic target. The basic concepts in cell migration are well established, but 
the details how these processes are regulated and executed are far from clear. The main 
principle of cell migration is simple; the cell must convert the intracellular forces generated 
by the rearrangement of the actin cytoskeleton to cell body translocation (Lauffenburger and 
Horwitz, 1996). The cells typically migrate in response to migratory signals. This cellular 
response can be either non-directional movement (chemokinesis) or directed migration 
along a chemical concentration gradient of the signal inducer (chemotaxis). In the initial 
phase of cell migration, the cells polarize and extend membrane processes such as 
lamellipodia and filopodia at the cell front. Lamellipodia are broad, sheet-like structures 
whereas filopodia are thin cylindrical needle-like projections (Lauffenburger and Horwitz, 
1996). Invadopodia are a specialized form of small needle-like projections in invasive cells 
being located beneath the cells rather than in the cell edge in a two-dimensional culture 
(Chen and Wang, 1999). The invadopodia have been characterized as highly dynamic 
structures where proteolytic degradation takes place (Chen, 1996; Chen and Wang, 1999; 
Mueller et al., 1999). Localized matrix degradation takes place also in the leading edge of 
the membrane extensions together with concomitant formation of nascent adhesive contacts 
by integrins and other adhesion molecules (Lauffenburger and Horwitz, 1996; Regen and 
Horwitz, 1992). These nascent adhesive sites may further develop to mature focal contacts, 
which are a highly dynamic protein network containing over fifty different proteins (Zamir 
and Geiger, 2001). 
 
Integrins are one of the key players in the regulation of cell migration. Integrins are a large 
family of heterodimeric cell adhesion molecules composed of an α chain and a β chain 
(Figure 5). Various combinations of the α and β chains bind specific cell surface and ECM 
ligands and transmit signals between the outside and inside of the cells (Giancotti and 
Ruoslahti, 1999; Hynes, 2002). For example, α5β1 binds fibronectin, whereas the αVβ5 is a 
vitronectin receptor. The ligand binding to integrins typically occurs through negatively 
charged residues present in the ligand such as the RGD motif (Arnaout et al., 2002; Hynes, 
2002). The binding site of these ligands is either the I domain in the α subunit of integrins or 
a binding pocket formed by the α and β subunit together as visualized in the αVβ3 integrin 
structure with the RGD peptide (Xiong et al., 2002). I domain-containing integrin α subunits 
include α1, α2, α10, α11, αL, αX, αD, αM and αE. All the other integrin α subunits lack an I 
domain (Hynes, 2002). Many integrins recognize a three amino acid motif RGD present in 
certain matrix proteins (Ruoslahti, 1996). RGD containing peptides have also been found by 
biopanning with these integrins (Healy et al., 1995; Koivunen et al., 1993; Koivunen et al., 
1995), whereas leukocyte β2 integrins recognize an LLG motif found by phage display 
(Koivunen et al., 2001). Studies with the leukocyte-specific β2 integrins have provided 
important information about integrin structure and function (Gahmberg, 1997). These 
integrins are also clinically highly relevant. Consequently, antagonists of the leukocyte 
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integrins αLβ2 and αMβ2 are being developed for the treatment of various autoimmune 
diseases and inflammatory conditions (Bansal et al., 2003; Shimaoka and Springer, 2003). 
 
 
 
Figure 5. Different combinations of integrin α and β subunits, and the domain organisation of the 
subunits. The I domain containing α subunits are shown with octagons and the leukocyte-
specific integrins are shaded with the grey box. PSI, plexin/semaphorin/integrin -homology 
domain; TM, transmembrane domain. Figure modified from (Hynes 2002, Shimaoka and 
Springer, 2003).  
 
The formation of the adhesive contacts is regulated by members of the Rho subfamily of 
GTPases, including Cdc42, Rac and Rho (Hall, 1994). For example, the Rho protein directly 
controls the formation of focal adhesions and actin stress fibers (Ridley and Hall, 1992). Not 
surprisingly, members of the rho family have frequently been associated with tumor 
metastasis (Clark et al., 2000; Jaffe and Hall, 2002; Suyama et al., 2003). Formation of the 
adhesive structures is accompanied by tyrosine phosphorylation of cytoskeleton-associated 
proteins such as focal adhesion kinase (FAK), paxillin and tensin, which are important 
mediators of intracellular signalling (Weisberg et al., 1997). FAK is a 125-kDa non-receptor 
tyrosine kinase that can be activated through integrin-mediated signals and regulates 
multiple functions such as cell motility, survival and proliferation (Giancotti and Ruoslahti, 
1999; Parsons et al., 2000). Increased FAK expression is a potent marker for the 
invasiveness of human tumors (Owens et al., 1995) and inhibition of FAK signalling 
through overexpression of a dominant negative mutant causes tumor dormancy (Aguirre 
Ghiso et al., 1999). FAK enhances cell motility and invasion by distinct mechanisms. FAK 
negative fibroblasts are defective in migration, but expression of viral Src-protein restores 
the motility through a reactivation of signalling through Src. The Src kinase associates with 
uPAR and integrins (Wei et al., 1999). Src acts by linking FAK to integrins, such as αVβ5 in 
VEGF mediated signalling (Eliceiri et al., 2002). However, invasion of FAK negative 
fibroblasts and expression of the gelatinases is not restored by v-Src. To become invasive, 
fibroblast cells require transient accumulation of FAK in lamellipodia and formation of 
FAK-Src-p130Cas-Dock180 signalling complex together with Rac activation (Hsia et al., 
2003). The authors suggested that FAK activity is required for the synchronization of cell 
motility and invasive behaviour. Recently, MT1-MMP and MT3-MMP activity was linked 
to proteolytic cleavage of FAK in vascular smooth muscle cells. However, it was not 
established if the cleavage was directly caused by the MT-MMPs (Shofuda et al., 2004). 
 
Generation of new adhesive sites is necessary but not sufficient for cell migration. The cells 
also need a mechanism to release the adhesions in the rear of the cells. In migrating 
fibroblasts, a major part of the integrins is left on the substratum by a mechanism called 
“membrane ripping” (Chen, 1981; Lauffenburger and Horwitz, 1996). The rest of the 
integrins are released from the substratum and re-distributed on the cell surface or 
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endocytosed (Palecek et al., 1996). The mechanism of the rear release potentially involves 
multiple mechanisms, including mechanical stress from the cytoskeleton and signalling 
pathways regulating integrin affinity (Lauffenburger and Horwitz, 1996). Proteases and 
protease inhibitors may contribute to this process. For example, the plasminogen activator 
inhibitor-1 can directly cause cellular detachment by inactivating the integrins (Czekay et 
al., 2003). Only a few other proteins have been shown to directly participate in cell 
detachment, namely tenascin-C, thrombospondin-1 and –2 and SPARC (secreted protein, 
acidic and rich in cysteine) (Murphy-Ullrich, 2001). The proteases can also indirectly 
modulate the affinity and hence the detachment of the cells by processing the extracellular 
matrix (Giannelli et al., 1997) or by cleaving integrin associated molecules (Andolfo et al., 
2002; Montuori et al., 2002). 
 
Thus, adhesion and detachment controlled by integrin-ligand interactions are one of the key 
regulators of cell migration. Migration of cells and the speed of migration can be regulated 
by ligand levels, integrin levels and the integrin-ligand affinities. Experimentally, the 
migration speed is biphasic, too little or too much adhesion strength will decrease the cell 
velocity, irrespective if this has been obtained by increasing ligand or integrin concentration 
or the integrin affinity to the ligand (Palecek et al., 1997). Indeed, these studies suggest that 
relatively small changes in integrin expression or affinity can substantially alter the speed of 
migration. Furthermore, inhibition of cell migration can thus be obtained not only with 
integrin-function blocking antibodies but also with antibodies that induce the activation of 
integrins (Palecek et al., 1997) and proteases that change the affinity of the matrix ligand to 
the integrin (Schenk and Quaranta, 2003). 
 
A possible complication in cancer therapy with cell migration inhibiting agents is that the 
migration mechanisms utilized by the cancerous cells and non-neoplastic cell are highly 
similar or identical. Migration of non-neoplastic cells is required for example in 
embryogenesis, inflammation and wound healing. Hence, inhibition of these activities may 
have detrimental side-effects (Friedl and Brocker, 2000; Lauffenburger and Horwitz, 1996). 
 
Multiple roles of proteinases in cell migration and invasion 
 
Tumor invasion is defined as penetration of the tissue barriers, such as the basement 
membrane by the migrating cancerous cells (Dano et al., 1985; Mignatti and Rifkin, 1993; 
Wolf et al., 2003). As discussed above, cell migration and invasion are distinct but 
coordinately regulated phenomena (Hsia et al., 2003). During the tumor progression, 
invasive capacity is required at multiple steps. Tumor cells frequently invade the 
surrounding tissue when the tumor starts to grow. Next, the capillary endothelial cells must 
invade the tumor and create the tumor blood vessels. Thereafter, some tumor cells 
intravasate into the blood circulation for metastasis, whereas the host immune cells invade 
the tumor. Last, the tumor cells must arrest in the distant organs, extravasate and migrate 
into the new metastatic site and start the invasive cycle again (Mignatti and Rifkin, 1993). 
Typically, alternating cycles of proteolysis and its inhibition occur in the tissues in order to 
control the protease activity. It was originally thought that the protease activity is only 
required for the degradation of the underlying matrix. It has now become evident that 
proteases also generate promigratory signals by cleavage of latent growth factors or by 
disrupting cell-cell contacts mediated by E-cadherin (Figure 6). The gelatinases actively 
participate in the activation of latent growth factors, MMP-9 being able to release active 
VEGF and TGF-β, thus promoting angiogenesis and tumor growth (Bergers et al., 2000; Yu 
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and Stamenkovic, 2000). The proteases can also release protein fragments and growth 
factors with chemotactic activity from the ECM, and expose migration promoting cryptic 
epitopes (Schenk and Quaranta, 2003; Stetler-Stevenson and Yu, 2001). 
 
 
Figure 6. Functions of MMPs in cell migration and invasion. 
 
Although proteases clearly stimulate cell migration in several ocassions, current evidence 
suggests that protease activity per se is not always essential. It has become clear that 
protease-independent migration strategies exist. Recently it was shown that catalytically 
inactive MT1-MMP mutant supported cell migration similarly to the wild type enzyme and 
the cell migration supporting activity was accounted for the catalytic domain and the C- 
terminal domain (Cao et al., 2004). Other investigators have similarly suggested a migration 
inducing ability of MMP-9 independent of the catalytic activity (Sanceau et al., 2003). 
Despite complete pharmacological inhibition of protease activity, many cells continue to 
migrate by utilizing existing pathways in the matrix and migrating by an ameboid-like 
movement. For example, T cells, HT1080 fibrosarcoma cells and MDA-MB-231 breast 
carcinoma cells can migrate in this manner (Wolf et al., 2003). Whether protease-
interactions that are independent of the proteolytic activity are required in this kind of 
migration is not known. The protease-independent mode of cell migration may explain the 
observations that MMP-9 is required for neutrophil transmigration through the endothelium 
in some but not all in vivo models (Betsuyaku et al., 1999; D'Haese et al., 2000). 
 
The gelatinases are also linked to the cell spreading and cytoskeletal changes during cell 
migration. Activated RhoA, the regulator of focal adhesions is necessary, but not sufficient 
for invasion (Stam et al., 1998). MMP-9 colocalizes with RhoA, which is a regulator of cell 
spreading in endothelial cells and expression of a constitutively active RhoA increases 
MMP-9 secretion (Abecassis et al., 2003). However, these results are contradictory to the 
results with RNA interference of MMP-9, which show that RhoA is inactive in the presence 
of MMP-9 and inhibition of MMP-9 expression decreases cell spreading (Sanceau et al., 
2003). It has been shown that inhibition of Rho by overexpression of a dominant negative 
mutant inhibits invasion but as well overexpression of Rho reduces invasiveness (Banyard 
et al., 2000). These contradictory results may be explained by the finding that fluctuating 
levels of active Rho, rather than constitutively active Rho, are required for efficient invasion 
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(Lin et al., 1999). Other evidence for the involvement of gelatinases in cell spreading comes 
from the studies with MMP inhibitors. MMP-2 inhibition by overexpression of TIMP-2 
causes extensive spreading of cells (Ray and Stetler-Stevenson, 1995). Many proteases, 
including the gelatinases accumulate into focal adhesions. For example, the gelatinases are 
found in the focal adhesions of endothelial cells (Partridge et al., 1997), and both TIMPs 
and chemical MMP-inhibitors stabilize the focal adhesion contacts of fibroblasts (Ho et al., 
2001). Conversely, overexpression of MMPs may destabilize focal adhesions (Shofuda et 
al., 2004). It has been suggested that MMP inhibitors augment cell adhesion by preventing 
cadherin cleavage and stabilize cell-cell contacts by inhibiting ECM degradation and 
thereby maintain integrin-ECM adhesion and focal contact assembly (Ho et al., 2001). 
 
Cell surface associations of the gelatinases 
 
Controlling of the proteolytic activity at the cell surface greatly facilitates cell migration and 
invasion (Werb, 1997). Docking of the proteases on the cell surface provides a direct 
mechanism by which cells can utilize and direct the proteolytic activity into correct 
substrates. The cell surface binding may additionally protect the proteases from the action of 
soluble inhibitors by steric hindrance, although some inhibitors like TIMP-2 have relatively 
free access to the cell surface. It has been also shown that proteases may be released from 
the cells in such a high concentration that the extracellular inhibitor concentration is locally 
exceeded. Consequently a portion of the proteases remains uninhibited and is capable of 
focalized pericellular proteolysis for a short duration. This phenomenon has been called 
“quantum proteolysis” (Liou and Campbell, 1996). 
 
As mentioned earlier, stimulation of tumor cells with phorbol esters or growth factors 
induces proMMP-9 secretion. A small part of the secreted proMMP-9 is consequently 
observed on the cell surface of endothelial cells (Olson et al., 1998; Partridge et al., 1997), 
keratinocytes (Mäkelä et al., 1998), breast epithelial (Olson et al., 1998; Toth et al., 1997) 
and breast cancer cells (Mira et al., 1999), neutrophils (Gaudin et al., 1997; Owen et al., 
2003), and many types of cancer cells including pancreatic (Zucker et al., 1990), ovarian 
(Ellerbroek et al., 2001) and prostate cancer (Festuccia et al., 2000), mammary carcinoma 
(Yu and Stamenkovic, 1999; Yu and Stamenkovic, 2000), promyelotic leukemia (Fiore et 
al., 2002) and fibrosarcoma cells (Mazzieri et al., 1997). The cell surface-bound gelatinases 
play a role in cell migration. For example, human bronchial epithelial cells secrete MMP-9 
in an actin-dependent manner to the leading edge of migrating cells. MMP-9 activity in 
these cells was required specifically for cell migration and not adhesion or spreading 
(Legrand et al., 1999). Although the mechanisms by which the MMP-9 is localized on the 
cell surface appear to be redundant, there are a few important similarities. First, it appears 
that the cell-surface bound MMP-9 is often free of TIMP-1. This has been observed in 
breast epithelial cells as well as in neutrophils (Owen et al., 2003; Toth et al., 1997). 
Second, in most studies cell surface localized MMP-9 is found in the proenzyme form 
(Gaudin et al., 1997; Mazzieri et al., 1997; Olson et al., 1998; Toth et al., 1997; Zucker et 
al., 1990). The inhibitor-free proenzyme is thought to be highly susceptible for activation. 
 
Multiple binding mechanisms of MMP-2 and -9 on the cell surface have been identified 
(Figure 7) On the surface of MCF10A breast epithelial cells, HT1080 fibrosarcoma and 
other tumor cells, proMMP-9 can associate with the α2(IV) chain of collagen type IV, 
whereas the affinity of MMP-2 to this collagen chain is much lower (Olson et al., 1998; 
Toth et al., 1999). This interaction is likely mediated through the collagen-binding domain 
 38
as TIMP-1 does not inhibit this interaction (Olson et al., 1998). The CBD of MMP-2 is also 
utilized for binding to the cell surface of normal fibroblasts. In a coculture system, 
fibronectin present on the surface of cancer cells competes with the fibroblast-associated 
MMP-2 liberating soluble MMP-2 (Saad et al., 2002). On the fibroblast surface, MMP-2 
binds to collagens, likely the α1 and α2 chains of type I collagen, with a possible 
involvement of β1 integrins binding to these collagen chains (Steffensen et al., 1998). 
Again, the CBD-mediated cell surface association of MMP-2 appears to be TIMP-
independent, as the activation of MMP-2 on fibroblasts is markedly elevated by competing 
the cell surface bound MMP-2 with recombinant CBD (Steffensen et al., 1998). 
 
A specific splicing variant of the hyaluronan receptor CD44 is involved in cell-surface 
association of MMP-9 in mouse mammary carcinoma and human melanoma cells. 
Disruption of this binding by overexpression of a soluble CD44 inhibits tumor invasion in 
vivo (Yu and Stamenkovic, 1999). MT1-MMP may regulate this interaction as it 
proteolytically processes CD44. Curiously, this cleavage results in enhanced cell migration 
(Kajita et al., 2001). The interactions of CD44 with MMP-9 are complex, as it has been 
observed that in osteoclast-like cells hyaluronan binding to CD44 downregulates MMP-9 
expression (Spessotto et al., 2002). The interaction mechanism of CD44 with MMP-9 is not 
known, however, MT1-MMP utilizes the hemopexin-like domain for its interaction with 
CD44 (Mori et al., 2002). MMP-9 interacts with CD44 in invadopodia (Bourguignon et al., 
1998). These are the same cellular structures, which also contain MMP-2 and αVβ3 
complexes (Deryugina et al., 2001) together with MT1-MMP (Nakahara et al., 1997). In 
leukemic cells, proMMP-9 has been observed to interact with intercellular adhesion 
molecule-1 (ICAM-1), which was identified as a substrate for MMP-9 (Fiore et al., 2002). 
Shedding of ICAM-1 by MMP-9 was found to enhance tumor cell resistance to natural 
killer cell-mediated cytotoxicity indicating an additional mechanism whereby MMP-9 may 
affect tumor growth (Fiore et al., 2002). 
 
Another cell surface receptor for the gelatinases is the low-density lipoprotein-related 
scavenger receptor (LRP). As mentioned before, MMP-2 and -9 can be internalized through 
this receptor (Hahn-Dantona et al., 2001; Yang et al., 2001). Although in most cases the 
gelatinases promote cell migration and invasion, other activities of the gelatinases may 
counteract this effect. For example, MMP-9 has been found to inhibit corneal re-
epithelialization by controlling cell replication (Mohan et al., 2002). Thus, it is not clear 
how the endocytic removal of gelatinases affects cell migration and invasion. The RECK 
protein is another cell-surface receptor for MMP-9 and MMP-2 although direct 
experimental evidence demonstrating the interactions of gelatinases with RECK is still 
lacking. Because RECK inhibits MMP activity, it probably preferentially binds the active 
gelatinases. Other receptors for gelatinases may also exist. MT2-MMP mediated activation 
of MMP-2 involves TIMP-independent C-terminal domain interactions on the cell surface, 
but the receptor has not been identified (Morrison et al., 2001). 
 
Integrins not only recognize various structural proteins, but they also act as receptors for 
proteases, including the MMPs. The αVβ3 integrin recognizes the C-terminal domain of 
MMP-2 and is able to localize MMP-2 on the cell surface. More specifically, MMP-2 
localizes with MT1-MMP, TIMP-2 and αVβ3 integrin in specific membrane microdomains 
called caveolae as well as in invadopodia and in the leading edge of the migrating cells 
(Nabeshima et al., 2000; Puyraimond et al., 2001). In some models, the cell surface activity 
of MMP-2 was found to be dependent on the αVβ3 integrin interaction and this interaction 
was necessary for tumor angiogenesis (Brooks et al., 1998; Brooks et al., 1996). Delivery of 
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the MMP-2 C-terminal domain as a recombinant protein or via viral infection also potently 
suppressed angiogenesis (Pfeifer et al., 2000). The C-terminal domain of MMP-2 appears to 
be a naturally occuring proteolytic fragment and an inhibitor of pericellular MMP-2 activity 
(Bello et al., 2001; Brooks et al., 1998). A small molecule inhibitor named TSRI265 has 
been identified as a compound being able to block the interaction of MMP-2 and αVβ3 
integrin, but it did not inhibit MMP-2 activity. A labelled derivative of TSRI265 bound to 
the αVβ3 integrin and not to MMP-2. Similarly to the C-terminal domain of MMP-2, 
TSRI265 inhibited angiogenesis indicating that MMP-2 must be localized on the cell 
surface to perform at least some of its biological functions (Boger et al., 2001; Silletti et al., 
2001). 
 
Figure 7. Cell surface interactions of the gelatinases. Many of the functions and interaction 
mechanisms are still hypothetical. Additional binding partners such as MT1-MMP (Zucker et al., 
2003) have been omitted for simplicity (see text for details). 
 
Interestingly, the binding of MMP-2 C-terminal domain to the αVβ3 integrin is RGD-
independent and does not compete with vitronectin binding to the αVβ3. Neither does the 
TSRI265 affect vitronectin binding (Brooks et al., 1998; Silletti et al., 2001). RGD-
independent binding to αVβ3 integrin is not unique for MMP-2 as the binding of tumstatin, a 
proteolytic fragment of type IV collagen α3 chain is RGD-independent (Maeshima et al., 
2001). Unfortunately, the binding sites of MMP-2 and tumstatin in the integrin have not 
been elucidated. The presence of two or more binding sites in the αVβ3 integrin suggests that 
integrins are able to gather many proteins to a single complex. This is apparently a 
necessary trait for efficient cell migration. 
 
MMP-9 has been observed to associate with α5β1 integrin in epithelial cells grown on 
fibronectin. The association could be modulated with gangliosides, suggesting that MMP-9 
localizes to specific cell surface lipid microdomains (Dolo et al., 2000; Wang et al., 2003). 
However, direct interactions of MMP-9 with α5β1 integrin or any other integrins have not 
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been demonstrated. Activated αVβ3 functionally co-operates with MMP-9, because MMP-9 
stimulates αVβ3-dependent migration of breast cancer cells (Rolli et al., 2003). Similarly, co-
operation of α3β1 integrin and MMP-9 in tumor invasion has been observed (Morini et al., 
2000). MMP-9 also cooperates with αVβ5 integrin. Insulin like growth factor-1 (IGF-1) 
mediated induction of cell migration coincides with MMP-9 expression and activity in 
MCF-7 breast cancer cells. The migration was specifically inhibited by a broad spectrum 
MMP inhibitor (Mira et al., 1999). However, MMP-9 is not absolutely required for the IGF-
1 mediated migration, as CS-1 melanoma cells transfected with αVβ5 integrin also migrate in 
response to the IGF-1 stimulation (Brooks et al., 1997) despite not expressing MMP-9 and 
only minimally MMP-2 (Brooks et al., 1998). Of considerable interest is the finding that 
there are two angiogenic pathways, which are differentially regulated by the αVβ3 and αVβ5 
integrins (Friedlander et al., 1995). Angiogenesis induced by bFGF and TNF-α is mediated 
through αVβ3 integrins, whereas VEGF, TGF-α and phorbol ester acting through protein 
kinase C act through αVβ5 integrins. Given that MMP-2 interaction with αVβ3 integrins is 
critical for the angiogenic response, it is possible that MMP-9 could be similarly involved in 
the αVβ5 integrin mediated angiogenic response as MMP-9 expression is induced by protein 
kinase C activation.  
Other proteases in cell migration and invasion 
 
Cell surface protease activity is typically observed in highly migratory cells and it is 
localized in the leading edge of the migrating cells as well as invadopodia (Artym et al., 
2002; Mueller et al., 1999). After the initial finding that MMP-2 can directly interact with 
the αVβ3 integrin, it has been found that several other proteases function similarly. MMP-1 
binds to α1β1 and α2β1 integrins (Stricker et al., 2001), whereas MT1-MMP associates with 
β3 or β1 integrins on endothelial cells depending on the extracellular matrix (Galvez et al., 
2002). Other proteases than MMPs may also interact with integrins. These include 
uPA/uPAR, which may interact with several integrins (Aguirre Ghiso et al., 1999; Carriero 
et al., 1999; Wei et al., 2001; Wei et al., 1996; Xue et al., 1997), elastase with αMβ2 integrin 
(Cai and Wright, 1996), snake venom disintegrin/metalloproteinase with α2β1 integrin 
(Ivaska et al., 1999) and ADAMs with several integrins (Bax et al., 2004; Bridges et al., 
2002; Nath et al., 1999). 
 
The serine protease urokinase-plasminogen activator (uPA) together with its receptor uPAR 
is one of the most characterized proteolytic systems. Initially uPA and uPAR were thought 
to be mainly responsible for plasminogen activation on the cell surface, but later studies 
have shown that uPA and uPAR have also direct and essential roles in cell adhesion, 
migration, differentiation and proliferation. Many of these functions appear to be signalling-
dependent processes and independent on the proteolytic activity (Blasi and Carmeliet, 
2002). uPA is expressed as a single chain precursor, which may be activated by many 
proteases including plasmin, trypsin or the gelatinases (Dano et al., 1985; Ellis, 2003; 
Koivunen et al., 1989; Prager et al., 2003). The single chain uPA can be cleaved either to a 
52 kDa or 33 kDa active two-chain molecule. uPAR is a GPI-anchored membrane protein 
and responsible for the localized plasminogen activation on the cell surface. More 
specifically, uPA and uPAR are localized in focal contacts and at areas of cell-cell contacts 
(Pöllänen et al., 1988; Pöllänen et al., 1987). The binding of uPA to uPAR greatly 
accelerates plasminogen activation because the receptor-bound uPA appears to mediate the 
assembly of catalytically favored complexes with cell-associated plasminogen (Ellis et al., 
1999). The ability of uPAR to mediate various signals inside the cells in the absence of an 
intracellular domain is still incompletely understood. It appears that the signalling is largely 
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mediated through integrins, which interact with uPAR on the cell surface. It was initially 
found that uPAR binds to β1 and β2 integrins and regulates integrin functions (Wei et al., 
1996). Later studies revealed that β3 and β5 integrins also associate with uPAR (Aguirre 
Ghiso et al., 1999; Carriero et al., 1999; Wei et al., 2001; Xue et al., 1997). Interestingly, 
the association of uPA/uPAR system with integrins is dependent on the ECM and directly 
influences the migration of cells (Wei et al., 2001; Xue et al., 1997). Expression levels of 
uPAR in vivo are directly related to their invasiveness and the rate of the tumor growth. 
uPAR deficient cells cease to grow and enter a state of dormancy in vivo (Yu et al., 1997) 
and this effect is mediated by the α5β1 integrin and MAPK signalling (Aguirre Ghiso et al., 
1999). Down-regulation of uPAR also reduces the intravasation of tumor cells in a chicken 
chorionallantoic membrane (CAM) model (Kim et al., 1998). 
 
uPA and its receptor uPAR are also able to regulate the activation-state of the integrins. The 
order of events occuring on the cell surface is far from clear. Some studies show that 
integrin activation by antibodies or divalent cations blocks uPA and MMP-2 activation and 
that MMP-2 activates uPA (Prager et al., 2003; Yan et al., 2000). This suggests that uPA 
and MMPs are activated prior to integrin activation and remain associated to the integrins. 
Furthermore, uPAR can be cleaved by uPA (Hoyer-Hansen et al., 1992) or MMPs in vitro 
(Andolfo et al., 2002; Koolwijk et al., 2001) and the cleaved uPAR form is also found in 
invasive tumor xenografts (Solberg et al., 1994). The cleavage occurs between domains 1 
and 2 impairs uPA and integrin binding (Montuori et al., 2002) and exposes a chemotactic 
epitope (Fazioli et al., 1997) suggesting that this cleavage is one of the cell migration 
regulating events on the cell surface. 
 
A number of other serine proteases have been implicated in tumor invasion. Trypsin-2 is a 
tumor-associated protease (Koivunen et al., 1989), which activates MMP-1, -3, -8, -9 and –
13 (Moilanen et al., 2003; Sorsa et al., 1997) and pro-urokinase (Koivunen et al., 1989). 
Trypsin activation of MMP-9 enhances tongue carcinoma cell invasion in the CAM model 
(Nyberg et al., 2002). Seprase is a membrane-bound serine-protease with gelatinase activity 
(Monsky et al., 1994). It associates with α3β1 integrins on collagen type I matrix in the 
invadopodia of invasive melanoma cells (Mueller et al., 1999). In addition, seprase 
associates with uPAR and dipeptidyl peptidase IV regulating invasion and migration of 
fibroblast cells (Ghersi et al., 2002). Seprase activity is also associated with increased 
metastasis in vivo (Iwasa et al., 2003). Hepsin is a type II transmembrane serine protease 
normally expressed in hepatocytes (Leytus et al., 1988). Microarray analyses have 
consistently found it to be one of the most upregulated genes in advanced prostate cancer 
(Dhanasekaran et al., 2001; Magee et al., 2001). Other transmembrane serine proteases 
implicated in cancer progression are membrane-type serine protease-1/matriptase in breast 
cancer (Shi et al., 1993), TMPRSS2 in prostate cancer (Afar et al., 2001) and TMPRSS4 in 
pancreatic cancer (Gress et al., 1997). 
 
Cathepsin B, a lysosomal cysteine protease can be localized on the surface of invasive cells 
through an interaction with annexin II tetramer (Mai et al., 2000). Cathepsin B can degrade 
many ECM proteins as well as activate other proteases on the cell surface (Podgorski and 
Sloane, 2003). ADAMs (A disintegrin and metalloproteinase) and ADAMTS (ADAM with 
a thrombospondin motif) are a large family of proteins involved in fertilization, 
neurogenesis, myogenesis and inflammatory response (reviewed in Primakoff and Myles, 
2000 and Tang, 2001). The major diffrerence between ADAMs and ADAMTS is that 
ADAMs are membrane proteases, whereas the ADAMTs are soluble ECM proteins 
(Primakoff and Myles, 2000). Interestingly, only slightly more than half of the 
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ADAMS/ADAMTS are functional metalloproteases due to mutations in the active site. 
Maybe the most important of these catalytically active proteases is tumor TNF-α converting 
enzyme (TACE/ADAM-17). It is a major inflammatory protease and several inhibitors have 
been developed to target it (Black, 2002). In addition, ADAMs may function as adhesion 
molecules through their disintegrin and cystein-rich domains. In contrast to MMPs, which 
have widely overlapping substrate specificities, ADAMs have much less common 
substrates. The ADAMs have also been implicated as binding partners with integrins. For 
example, ADAM-28 interacts with α4β1 integrin (Bridges et al., 2002), ADAM-15 binds to 
both αVβ3 and α5β1 integrins (Nath et al., 1999) and TACE/ADAM-17 associates with α5β1 
integrin (Bax et al., 2004). 
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GELATINASES IN TUMOR PROGRESSION 
  
Enhanced expression of MMP-2 and MMP-9 has been observed in cancers of breast, colon, 
lung, skin, ovary and prostate among others (reviewed by Egeblad and Werb, 2002). 
Increased gelatinase expression in these cancers is often accompanied with increased 
invasiveness and metastasis as well as decreased overall survival. Interestingly, MMP 
expression may be dependent on the stage of the cancer. In melanoma, increased expression 
of MMP-9 is found in the early steps, but at a later stage the opposite is true (van den Oord 
et al., 1997). In breast and colon cancer MMP-9 expression has been correlated with both 
increased and decreased survival and formation of distant metastasis (Pacheco et al., 1998; 
Scorilas et al., 2001; Takeha et al., 1997; Zeng et al., 1996). The current view is that the 
gelatinases and other MMPs are needed at multiple stages during the tumor progression and 
different tumors may utilize different MMPs. The steps where MMPs are involved include 
the growth of the primary tumor, angiogenesis, intravasation of the tumor cells, migration 
and invasion of the metastatic cells in the secondary organ as well as initiation and support 
of the tumor growth in the metastatic site (Figure 8). Furthermore, MMPs may either 
promote or suppress tumor progression by cleaving various bioactive substrates (see below). 
Thus, the final effect of gelatinases on tumor progression is highly context-dependent. 
   
 
Figure 8. Schematic representation of the 
steps in tumor progression. Gelatinases or 
other MMPs have been implicated to play 
a role in most of these steps. Note that 
tumors contain in their stromal 
compartment nonmalignant cells such as 
fibroblasts and immune/inflammatory cells, 
which may act as a source for MMPs and 
other molecules to nourish the tumor 
development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Angiogenesis 
 
Angiogenesis, the formation of new blood vessels is a crucial process during the 
development. Angiogenesis was also realized to be a necessary step for tumor progression 
as without the nutrient and oxygen supply from the new blood vessels tumors ceased to 
grow beyond a certain size (reviewed by Folkman, 1992; Veikkola and Alitalo, 1999). This 
conception has yielded a myriad of strategies to inhibit tumor growth by angiogenesis 
modulators. These include protease inhibitors, inhibitors of growth factors and growth factor 
receptors, integrin inhibitors, inhibitors of signalling cascades and many other agents with 
undefined mechanisms (Cristofanilli et al., 2002). MMPs and especially the gelatinases are 
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critically involved in angiogenesis in vitro (Schnaper et al., 1993; Seftor et al., 2001) and in 
vivo (Itoh et al., 1998; Vu et al., 1998). The exact mechanisms how the gelatinases 
contribute to angiogenesis still remain obscure and may include multiple pathways. For 
example, TGF-β or phorbol ester-induced MMP-9 expression and proteolytic potential did 
not directly correlate with endothelial cell motility and in vitro angiogenesis (Puyraimond et 
al., 1999). The most direct evidence for gelatinases in angiogenesis comes from the studies 
of the initial steps in tumor angiogenesis. In a model of carcinogenesis of pancreatic islets in 
RIP1-Tag2 transgenic mice, MMP-2 and MMP-9 were found to be upregulated in 
angiogenic lesions. The upregulation of the gelatinases resulted in the release of bioactive 
VEGF, which is a major promoter of angiogenesis. Using MMP-2 and MMP-9 knockout 
mice, the switching from the quiescent to the angiogenic stage was found to be due to 
MMP-9 activity. MMP-2 deficiency did not impair the angiogenic switch but reduced the 
rate of tumor growth (Bergers et al., 2000). In the tumor tissue the main source of MMP-9 
appeared to be the tumor-infiltrating inflammatory cells (Bergers et al., 2000; Coussens et 
al., 2000). However, the angiogenic switching is not solely due to to MMP-9 activity as 
cysteine cathepsin inhibitors also inhibit this process (Joyce et al., 2004). 
 
In a retinal neo-vascularization model MMP-9 activity was required to expose a cryptic pro-
migratory control site in collagen (Hangai et al., 2002). A monoclonal antibody HUIV26 
recognizes an epitope in denaturated collagen type IV. Exposure of this epitope is required 
for angiogenesis in vivo and is associated with αVβ3 binding to collagen type IV. In contrast 
to retina, in melanoma vasculature the appearance of HUIV26 epitope is concomitant with 
the appearance of active MMP-2 (Xu et al., 2001). MMPs are also involved in 
developmental angiogenesis as MMP-9 and MT1-MMP deficient mice show skeletal 
abnormalities due to a delayed vascular invasion of the cartilage (Holmbeck et al., 1999; Vu 
et al., 1998; Zhou et al., 2000). 
 
Metastasis 
 
Metastasis is the spread of cancer cells from the primary tumor to the new metastatic sites 
via blood or lymph vessels (reviewed by Stacker et al., 2002). Metastasis is a highly 
inefficient but a deadly process (Weiss, 1990). It was long thought that some tumor cells 
aquire new mutations not initially present in the primary tumor cells making them 
metastatic. Later on, it was suggested that metastatic cells have an intrinsic signature 
pattern, the “poor-prognosis signature” that accounts for their metastatic behaviour. A recent 
study has merged these metastasis theories by showing that in addition to a poor-prognosis 
signature, the metastatic cells must activate additional genes, which are not activated in the 
primary tumor (Kang et al., 2003). Although no single gene has been identified as a major 
regulator of metastasis in all tumors, many animal models indicate a critical role for the 
MMPs, including MMP-2 and MMP-9. For example, gene expression analysis of human 
tumors has linked MMP-9 with a poor prognosis in breast cancer (van 't Veer et al., 2002). 
In an experimental metastasis assay, intravenously injected melanoma or lung carcinoma 
cells showed significantly decreased number of metastatic colonies in MMP-9 deficient 
mice (Itoh et al., 1999). These results highlight the importance of host-derived MMPs in the 
metastatic process. Indeed, MMP-2 and MMP-9 are often derived from the stromal cells 
such as fibroblasts, myofibroblasts, immune cells and endothelial cells surrounding the 
tumor cells, and this appears to be a common theme for most MMPs (Nelson et al., 2000; 
Polette et al., 1994). Other experiments have shown contribution of MMP-9 in the lung 
metastasis induced by VEGF receptor-1. In these experiments MMP-9 was upregulated in 
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premetastatic lung endothelial cells as well as macrophages and MMP-9 deficiency led to a 
marked reduction in metastasis (Hiratsuka et al., 2002). 
 
Intravasation, the invasion of the tumor cells to the blood circulation is a critical step in the 
metastatic process. Using the CAM assay, uPA and MMP-9, have been identified as critical 
players in the intravasation process (Kim et al., 1998). Intravasation was dependent on both 
urokinase and MMP-9, as in the absence of uPA or MMP-9, tumor cells showed only low 
levels of intravasation. These proteases may act in concert with the integrins as αVβ5 is also 
required for tumor cell dissemination in the CAM model (Brooks et al., 1997). Furthermore, 
αVβ5, but not αVβ3 mediated migration and metastasis requires growth factor-mediated 
tyrosine kinase signalling, such as the action of insulin-like growth factor (Filardo et al., 
1995; Klemke et al., 1994), which also upregulates uPA and MMP-9 (Dunn et al., 2001; 
Mira et al., 1999). The proteins implicated in the metastatic process form an interesting 
functional loop. First, receptor bound uPA is essential for αVβ5 mediated cell migration 
(Yebra et al., 1996). On the other hand SPARC protein is required for αVβ5 dependent 
metastasis to bone (De et al., 2003). SPARC also induces MMP-1, -3 and –9 expression 
(Tremble et al., 1993), and the MMPs may be activated by uPA-mediated processes 
(Mazzieri et al., 1997; Ramos-DeSimone et al., 1999). Furthermore, SPARC can be 
proteolytically processed by MMPs (Sasaki et al., 1997), and the MMP-cleaved SPARC 
fragments modulate cell proliferation, migration and angiogenesis (Sage et al., 2003). 
 
In contrast, extravasation, the entrance of tumor cells from the circulation to the tissues, is 
not critically dependent on the MMP activity. TIMP-1 overexpressing melanoma cells do 
not have any defect in the extravasation ability, but do show a decreased number and size of 
metastases after extravasation indicating a critical role for MMPs in the subsequent tumor 
growth (Koop et al., 1994). Similar results have also been obtained using tumor cell lines 
with low and high metastatic potential in mice and in the CAM assay. No difference in the 
extravasation rate was observed, whereas subsequent migration in the tissue and the rate of 
tumor cell proliferation were different (Koop et al., 1996; Morris et al., 1994). Thus 
whereas the spreading of the tumor cells into various organs from the primary tumor 
appears to be an efficient process, the subsequent growth of these metastasized cells is a 
rate-limiting step. Quantitative measurements on the individual steps in metastasis have 
confirmed that the ability of intravasation and the ability for growth expansion in the 
secondary organs are indeed the rate-limiting steps (Zijlstra et al., 2002). The mechanisms 
controlling the growth of the cancer cells in the secondary organs are not known in a detail. 
It is implausible that the cells would continuously proliferate in the metastatic site as it can 
take years before tumors can be detected in secondary organs. It thus seems that the cells 
either enter a state of dormancy or there is a balance of continuous proliferation and 
apoptosis in the micrometastasis. Both models are supported by experimental evidence. The 
tumor dormancy might be due to specific downregulation of cell surface molecules such as 
uPAR (Aguirre Ghiso et al., 1999) and angiogenic signals may then be used to terminate the 
dormant state (Udagawa et al., 2002). MMPs apparently also participate at this step as 
TIMP-1 expression by the tumor cells, but not by the surrounding tissue, significantly 
affects the initiation and growth of the tumors (Soloway et al., 1996). There are also 
evidence supporting the continuos proliferation/apoptosis model of metastases (Barnhill et 
al., 1998). 
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Cancer-associated inflammation 
 
It has been estimated that over 15% of the malignancies have an infectious origin (Kuper et 
al., 2000). In addition to these, the leukocytes participate in the tumor progression also in 
the absence of infectious agents.  Chronic inflammation associated with some cancers can 
further stimulate cancer progression due to the release of MMPs from the inflammatory 
cells (Coussens et al., 1999; Coussens et al., 2000). The critical role of MMP-9, apparently 
derived from leukocytes, in the initiation of angiogenesis was discussed above. Tumor cells 
produce an array of cytokines and chemokines that induce leukocyte infiltration to the 
tumor. The same cytokines and chemokines may also promote tumor growth by an 
autocrine mechanism. The tumor-infiltrated leukocytes, including neutrophils, dendritic 
cells, macrophages, eosinophils, mast cells and lymphocytes can extensively modify tumor 
microenvironment by producing additional cytokines, reactive oxygen species, proteases 
including MMPs, interferons and other compounds (Coussens and Werb, 2002). However, 
inflammation in cancer is a two-bladed sword as the compounds relased by the 
inflammatory cells may either suppress or enhance tumor progression. Thus, it appears that 
a delicate balance of pro- and anti-tumor activity defines the fate of the tumors; both 
excessive and inadequate exploitation of the inflammatory components produced by 
leukocytes and the other stromal cells is detrimental to the tumor growth (Coussens and 
Werb, 2002). 
 
Chemokines are important mediators of leukocyte recruitment into the tumors. In addition to 
their role in the regulation of directional migration of leukocytes, chemokines are also able 
to directly modify endothelial and tumor cell chemotaxis and thus affect migratory and 
invasive behaviour of the tumor. Some chemokines may inhibit directly or indirectly 
angiogenesis, whereas others are proangiogenic. Furthermore, chemokines may be 
proteolytically processed to regulate their activity. For example, monokine induced by 
interferon IFN-γ (MIG), platelet factor (PF)-4, interferon-inducible protein-10 (IP-
10/CXCL-10) and stromal-cell derived factor (SDF)-1 are angiostatic chemokines (Moore et 
al., 1998), which can be cleaved by the gelatinases thus potentially enhancing angiogenesis. 
Similarly, the gelatinases can process angiogenic chemokines including granulocyte 
chemotactic protein (GCP)-2, epithelial-cell derived neutrophil activating peptide (ENA)-
78, growth-regulated oncogene (GRO)-α and pro-interleukin-8 (Moore et al., 1998) (see 
Table 1). Some chemokines also participate in the homing of tumor cells into the metastatic 
sites (Muller et al., 2001; Nathanson, 2003). Hence, the gelatinases may affect metastasis 
also by regulating chemokine activity. The gelatinases, especially MMP-9, have been 
implicated in the negative regulation of immune response to cancer by cleaving the 
interleukin-2α receptor, activation of TGF-β and by shedding of ICAM-1 (Fiore et al., 2002; 
Sheu et al., 2001; Yu and Stamenkovic, 2000). MMP-2 is able to proteolytically process 
monocyte chemoattractant proteins and suppress inflammation in vivo (McQuibban et al., 
2002). 
 
As the action of inflammatory cells is intimately involved in tumor progression, the use of 
anti-inflammatory agents, such as the cyclo-oxygenase inhibitors is an attractive approach 
for anti-cancer therapy (Liu et al., 2002; Williams et al., 1999). Another possibility could be 
the prevention of leukocyte migration into the tumors. The selective expression of β2 
integrins in leukocytes might provide a suitable therapeutic window, although leukocytes 
may also utilize other integrins for migration (Worthylake and Burridge, 2001). 
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Dual role of gelatinases in cancer 
 
Although inhibition of gelatinases in many cases results in regression of tumor growth, the 
gelatinases, especially MMP-9 can also stimulate tumor growth. Based on the data obtained 
with MMP and TIMP knockout animals, as well as with various in vitro models and clinical 
trials, it has become evident that gelatinases and other MMPs have both pro- and anti-
angiogenic properties. Furthermore, it has become evident that there are tissue- and tumor 
specific differences in the use of MMPs and TIMPs (reviewed by Egeblad and Werb, 2002). 
The dual role of MMPs in cancer is somewhat similar to the role of αV integrins. The αV 
integrin antagonists effectively suppress tumor angiogenesis in in vitro and in animal 
models (Brooks et al., 1994; Friedlander et al., 1995; Hammes et al., 1996). However, the 
knockout mice of αVβ3 and αVβ5 alone or in combination show increased angiogenesis and 
tumor growth (Hynes, 2002; Reynolds et al., 2002). Although genetic ablation of all αV 
integins is detrimental in mice, some of the pups were born alive. Extensive vasculogenesis 
was also observed implicating that these integrins are not the sole regulators of blood vessel 
formation (Bader, 1998).   
   
One of the anti-angiogenic activities of the MMPs, is the generation of angiostatin, a 
proteolytic fragment of plasminogen. As it name implies it is a negative regulator of 
angiogenesis. Of the MMPs, MMP-2, -7, -9 and -12 can generate angiostatin. This may be a 
crucial factor in controlling the growth rate of certain tumors. Tumors grown in integrin α1 
knockout mice were significantly smaller than those grown in wild type mice, these tumors 
also showed remarkably reduced angiogenesis and increased plasma angiostatin. In further 
experiments elevated levels of MMP-7 and MMP-9 were found to be responsible for 
angiostatin generation (Pozzi et al., 2000) and low plasma levels of MMP-9 were associated 
with increased angiogenesis (Pozzi et al., 2002). A similar effect would propably be 
observed by MMP-9-generated endostatin (Ferreras et al., 2000). A third anti-angiogenic 
protein generated by MMP-9 is tumstatin, a fragment from the noncollagenous domain of 
collagen type IV α3 chain. Interestingly, physiological concentrations of tumstatin 
effectively suppress tumor growth. MMP-9 deficient mice showed an accelerated rate of 
tumor growth after an initial lag period. This increased tumor growth was linked to the 
absence of tumstatin (Hamano et al., 2003). Tumstatin knockout mice similarly showed 
increased tumor growth associated with enhanced tumor angiogenesis. Interestingly, 
angiogenesis associated with the normal development and tissue repair was normal 
(Hamano et al., 2003). As discussed above, proteolytic processing of chemokines may be an 
additional level where the gelatinases may either suppress or enhance tumor progression. It 
is currently unclear to what extent this activity of gelatinases affects tumor growth. Other 
MMPs, however, have been implicated to play a role in the regulation of tumor-associated 
inflammation. MMP-8 deficient mice show an increased incidence of skin tumors in a 
chemical carcinogenesis model (Balbin et al., 2003). These mice also developed the tumors 
more rapidly than the wild-type mice and the observed effect could be tracked to a sustained 
inflammatory response in the tumor (Balbin et al., 2003). 
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THERAPEUTIC POSSIBILITIES WITH THE MMP INHIBITORS 
 
Despite the beneficial effects of MMP inhibitors in the in vitro assays and in animal models, 
most clinical trials so far have been disappointing. The reasons for these failures have been 
widely analyzed (Coussens et al., 2002; Hidalgo and Eckhardt, 2001; Overall and Lopez-
Otin, 2002; Pavlaki and Zucker, 2003). The main reason for the failures of MMP-inhibitors 
is that most clinical studies involved advanced stage cancers. It has now been established 
that the MMP-inhibitors such as marimastat are not particularly effective at the later stages 
as also shown with the mouse models (Bergers et al., 1999). Another reason for the failures 
is that no reliable biomarkers have been available for the evaluation of the efficacy of MMP 
inhibitors. Thus it has been utmost difficult or impossible to show that the inhibitors would 
have sufficiently inhibited their targets (Coussens et al., 2002). For example, analysis of the 
serum or plasma levels of MMPs has been largely uniformative (Hidalgo and Eckhardt, 
2001), but the recently developed MMP-activity imaging agents may alleviate this problem 
(Bremer et al., 2001). A further difficulty in the evaluation of MMP-inhibitor activity in the 
clinical trials is that the MMP inhibitors are not cytotoxic. Thus they do not directly cause 
shrinkage of the established tumors. This requires setting of new endpoints in the evaluation 
of drug efficacy. 
 
Moreover, the first clinical studies were initiated when there was only a limited knowledge 
on the role of various MMPs in cancer and they utilized broad-spectrum inhibitors of MMPs 
with little or no specificity towards individual proteases. Whether the more selective 
inhibitors will show any more benefit in the clinical trials is still a major question, as even a 
single MMP can have both pro- and anti-tumor activities. In accordance with this, the 
observations that some MMP-deficient mice show increased tumor growth, is a major 
concern (Balbin et al., 2003; Coussens et al., 2000; Hamano et al., 2003). Thus alternative 
and/or more selective MMP-inhibition strategies are likely to be required, but even their 
success cannot be guaranteed. 
 
Despite the poor success of most MMP inhibitor trials, important data has been accumulated 
supporting the development of MMP inhibitors as therapeutic agents. Phase I studies, which 
aim to evaluate the safety of the tested drug-candidates have established that the MMP 
inhibitors are in general safe and well tolerated. The main adverse effect of MMP-inhibitors 
has been musculoskeletal pain (Rosemurgy et al., 1999). The effect is propably due to 
inhibition of ADAMs, as those MMP inhibitors with a reduced activity to the ADAMs do 
not show these side-effects (Brown, 2000). Furthermore, not all trials have been failures. 
Marimastat has shown modest increase in overall survival of patients with gastric cancer 
and pancreatic cancer (Bramhall et al., 2002; Pavlaki and Zucker, 2003). 
 
MMP inhibitors are best viewed as anti-angiogenic agents for primary tumors and as agents 
to prevent metastasis. Before attempting cancer therapy with the MMP inhibitors, it would 
be beneficial to measure MMPs in tumors and blood as a means of identifying those who 
are likely to respond to the therapy (Zucker et al., 2000). However, as discussed above, the 
plasma levels of MMPs may not be sufficiently informative for this purpose. A combination 
therapy of MMP-inhibitor together with a cytotoxic drug seems to be a more attractive 
alternative. Some reports have indicated a synergistic effect of gelatinase selective inhibitors 
with apoptosis inducing agents in cell culture (Nyormoi et al., 2003). Animal models with a 
combination therapy have been promising, with reduced metastasis and increased survival 
(Haq et al., 2000; Liu et al., 2003; Yamamoto et al., 2003). As a consequence, several 
clinical studies with combination therapy are now in progress (Hoekstra et al., 2001; Nelson 
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et al., 2000), but the first failures with the combination therapy have been already reported 
(Bramhall et al., 2002). 
 
Several strategies have been suggested for the future MMP inhibitor trial development 
(Pavlaki and Zucker, 2003). These include inhibitors that can be administred for long 
periods of time without side-effects, combination of MMP inhibitors with other proteinase 
inhibitors, and inhibition of MMP synthesis, in addition to aforementioned design of more 
selective inhibitors and treating cancer at earlier stages. Alternatively, inhibition of localized 
MMP activity may be a potential inhibition approach as demonstrated by the inhibition of 
MMP-2 binding to the αVβ3 integrin without inhibition of MMP-2 activity (Silletti et al., 
2001). The overexpression of MMPs in cancer provides also alternative therapeutic 
approaches, independent on MMP inhibition. Targeting of drugs encapsulated into 
liposomes coated with MMP-targeting compounds is one possibility. Another novel use of 
MMPs is to use prodrugs that become cytotoxic upon proteolytic cleavage by an MMP 
(Kratz et al., 2001; Mansour et al., 2003) or MMP-activatable gene therapy vectors (Peng et 
al., 1997). As it is now evident that MMPs promote cancer progression mainly at the early 
stages, it is crucial to identify the primary tumors as early as possible. The MMP inhibitors 
coupled to imaging agents could be used to detect small tumors due to their tumor-targeting 
properties (Bremer et al., 2001; Li and Anderson, 2003; Medina et al., 2001). 
 
Finally, if cancer remains refractory to the treatment with the MMP inhibitors even after 
novel treatment strategies, various inflammatory, degenerative and vascular diseases could 
be other disease targets for these inhibitors. 
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AIMS OF THIS STUDY 
 
 
It has recently become evident that despite the widely observed association of gelatinase 
activity with the invasive capacity of cancer cells, the active site inhibitors of MMPs do not 
show beneficial effects in the treatment of human cancers. This is at least partially due to the 
fact that the exact biological functions of these enzymes are not fully understood. Some 
MMPs have been shown to bind cell surface receptors, such as integrins and CD44, and 
these interactions appear to play an important role in the regulation of MMP functions. To 
gain more insight into the functions of the gelatinases in cell migration and invasion, I have 
utilized phage display to unravel molecular details about the cell-surface interactions of 
MMP-9. Phage display is a powerful tool to identify peptides that bind to proteins and other 
biomolecules. The major advantage of phage display is that it offers unique information 
about protein-protein interactions and simultaneously provides novel means to inhibit these. 
However, the inherent proteinaceous nature of the identified peptide ligands may limit their 
utility in drug development. With these issues in mind I have focused on the identification 
and development of novel inhibitors of gelatinase-mediated cancer cell migration and 
invasion, and extended the utility of phage display technology. During the course of the 
work, the following questions were raised: 
 
 
1) How could phage display peptides be analysed more conveniently for 
activity and solubility properties, and could the activity and stability of the 
peptides be easily improved to extend the utility of these compounds? 
 
2) Which integrins, if any, act as receptors for MMP-9 on the surface of 
leukemia and fibrosarcoma cells, and what is the mechanism of binding? 
Are there any additional cell-surface interactions? 
 
3) Is prevention of cell-surface association of MMP-9 a feasible way to 
inhibit cancer cell migration and invasion? 
 
4) Could the peptides displayed on a phage be directly used to identify potent 
small-molecule compounds, which would better suit for drug 
development? 
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MATERIAL AND METHODS 
 
A summary of the methods used will be given. Detailed methods can be found in the 
original publications. 
 
Standard phage display. Phage display selections were made using a pool of random 
peptide libraries CX7-10C and X9-10 (Koivunen et al., 1999). The target proteins were 
immobilized on microtiter wells at a 2 µg/ml concentration. The phage library pool was 
added to the wells with or without a subtractive step with GST-coated wells. After three 
rounds of selection the phage sequences were determined by amplifying the peptide 
encoding sequences using primers F1-F 5’-TAA TAC GAC TCA CTA TAG GGC AAG 
CTG ATA AAC CGA TAC AAT-3’ and F1-R 5’-CCC TCA TAG TTA GCG TAA CGA 
TCT-3’. The PCR products were sequenced using the primer F1-S 5’-TAA ACC GAT ACA 
ATT AAA GGC TC-3’. The phage binding specificity was tested with immobilized proteins 
(20 ng/well). The phage (108 transducing units/well) were allowed to bind in the absence or 
presence of competitor peptides (20 µM) followed by washings with PBS-0.05% Tween20 
(PBST). The bound phage were detected with peroxidase-conjugated anti-phage antibody 
(Amersham Biosciences). 
 
Phage display with amino acid analogues. The fluorophage library was prepared from 15 
µl aliquots of CX7C and CX8C libraries infected to tryptophan auxotrophic MB5F strain. 
The phage-infected bacteria were transferred to a mimimal medium and cultured in the 
presence of 5-fluorotryptophan and 6-fluorotryptophan. The fluorophage library (a 20 µl 
aliquot) was added to the protein coated wells in 50 mM Tris-HCl, 150 mM NaCl (pH 7.5) 
containing 1% BSA. After extensive washings the bound phage were eluted and used to 
infect the MB5F strain. The infected bacteria were cultured overnight, transferred to M9 
medium containing tryptophan and again cultured overnight. The bacteria were transferred 
into 100 ml M9 medium with tryptophan and cultured until OD600 was 0.7-1.0. The 
bacteria were then resuspended into 100 ml of M9 medium containing 0.5 mM (as L-
isomer) 5FW and 6FW and cultured overnight. The phage were collected using PEG/NaCl 
precipitation. 
 
Preparation of auxotrophic bacterial strains. In vitro assembled bacteriophage Mu DNA 
transposition complexes were used to mutagenize the parental bacterial strains (Lamberg et 
al., 2002). The transposition complexes were electroporated into E. coli ER2566 or 
MC1061 strains. Successful transpositions were identified by gain of antibiotic resistance. 
The clones obtained were replica-plated on M9 minimal plates and M9 plates containing the 
amino acid to be screened for auxotrophism. The final strains ER2566/Trp82 and MB5F are 
auxotrophic for tryptophan and the MB64F is auxotrophic for methionine.  
 
Peptide biosynthesis. Recombinant peptides were cloned using oligonucleotides coding for 
the desired peptide or by PCR amplification from the peptide bearing phage using universal 
primers. The sequences for the universal primers are 5’-
CCTTTCTGCTCTTCCAACGCCGACGGGGCT-3’ and 5’-
ACTTTCAACCTGCAGTTACCCAGCGGCCCC-3’. The insert was digested with SapI 
and PstI and ligated into similarly digested pTwin vector (New England Biolabs). The 
presence of the correct insert was verified by DNA sequencing. The plasmid encoding the 
intein-peptide fusion was transformed into E. coli ER2566 strain. The bacteria were cultured 
in LB medium containing 100 µg/ml ampicillin and protein expression induced with IPTG 
(0.3 mM) The intein-peptide fusions were purified with chitin affinity chromatography. The 
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intein-cleavage reaction was performed on-column by overnight incubation in pH 7.0 buffer 
at room temperature. The free peptide was eluted, concentrated and purified with reverse-
phase HPLC. The identity of each peptide was verified by mass spectrometry. Peptides were 
quantified using o-phthalaldehyde or HPLC analysis. Tryptophan analogue containing 
peptides were expressed in the tryptophan auxotrophic ER2566/Trp82 in a minimal medium 
in the presence of 5-hydroxy-L-tryptophan, 5-fluoro-DL-tryptophan, 6-fluoro-DL-
tryptophan or DL-7-azatryptophan.  
  
Cell culture. Human HT1080 fibrosarcoma cells, human monocytic leukemia THP-1 cells, 
human acute myeloid leukemia OCI-AML-3, human histiocytic lymphoma U937 cells, 
human tongue squamous cell carcinoma cell line HSC-3, hamster melanoma cell line CS-1 
and the β5 integrin transfected derivative were maintained in DMEM or RPMI supplemented 
with 10% FBS, L-glutamine, penicillin and streptomycin. 
 
Cell adhesion, migration and invasion. Cell adhesion was studied by coating microtiter 
wells with various peptides or proteins. The cells were stimulated with 50 nM PDBu to 
activate the β2 integrins. Nonadherent cells were removed by gentle washing with PBS or in 
some cases with 2.5 mM EDTA in PBS and the adherent cells quantitated by measuring 
intracellular phosphatase activity using p-nitrophenyl phosphate as a substrate (Koivunen et 
al., 2001). Alternatively, THP-1 cells were stimulated with 20 nM PDBu and allowed to 
adhere on uncoated plastic overnight. Nonadherent cells were removed by washing with 
PBS followed by additional washes with 2.5 mM EDTA in PBS. Migration of HT1080, 
THP-1 and OCI-AML-3 cells was studied using transwells coated with various proteins. 
The cells (20 000-50 000/100 µl, depending on the experiment) were allowed to migrate in 
the presence of 10% serum containing culture medium. Invasion assays were conducted 
using Matrigel coated transwells (BD Biosciences). The cells migrated to the underside of 
the membrane were stained with crystal violet and counted under light microscope 
(Koivunen et al., 1999). 
 
Activation of the gelatinases. In vitro activation of MMP-2 was done with APMA and 
MMP-9 with trypsin or MMP-3. For the activation of MMP-9, THP-1 cells (40 000/100 µl) 
or confluent HT1080 cells were incubated for 16 h in the presence or absence of 2.5 µg/ml 
plasminogen, 0.5 µg/ml pro-MMP-3, 40 nM PDBu, and the peptides at a 200 µM 
concentration unless otherwise indicated. Aliquots of the conditioned media were analyzed 
by gelatin zymography. 
 
Gelatinase activity assays. Gelatinase inhibitory activity was determined using either one 
of the three assays: 1) The degradation of biotinylated gelatin was examined using a 
gelatinase activity kit according to the manufacturer’s instructions (Roche). 2) The 
degradation of a MMP-2 specific fluorescent peptide substrate MCA-Pro-Leu-Ala-Nva-
Dpa-Ala-Arg-NH2 (Calbiochem, 2.5µM final concentration) was analyzed using a MOS-
250 spectrofluorometer (Bio-Logic SA, Claix, France) with 330 nm excitation and 390 nm 
emission. 3) The degradation of β-casein was studied by incubating MMP-2 with 0.1 mg/ml 
concentration of β-casein for 2 h at 37°C followed by analysis by SDS-PAGE. 
  
Zymography. Gelatinases in the conditioned medium of the cultured cells were detected 
using gelatin co-polymerized in SDS-PAGE gels (Hibbs et al., 1985). Briefly, the samples 
were run in non-reducing conditions followed by washing of the gels to remove SDS and 
allow refolding of the gelatinases. The gels were then incubated in the gelatinase activity 
buffer for 16 hours followed by staining of the gels with coomassie brilliant blue. The 
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gelatinase activity is visualized as white bands on a uniform blue background. uPA activity 
was detected using plasminogen/casein zymography as described (Myöhänen et al., 2001). 
    
Expression of recombinant MMP and integrin domains. The following MMP constructs 
were cloned and expressed for this study. The collagen binding domain of MMP-9 (Gly204-
Gly373), the C-terminal domain of MMP-2 (Glu438-Cys631) and MMP-9 (Asp494-Asp688) and 
proMMP-9 with the hinge region and C-terminus deleted (proMMP-9-∆HC, Ala1-Gly424). 
These proteins were expressed in E. coli and purified using gelatin affinity or Ni2+-chelating 
affinity chromatography. The integrin β5 I-EGF2+3 fragment (Glu476-Asn563) was cloned 
from β5 cDNA and expressed with an N-terminal His6-tag. Single point mutations to MMP-
9, β5 I-EGF2+3 fragment and the αM I domain were prepared by site directed mutagenesis. 
 
ProMMP-9 and gelatin binding to leukocyte αM integrin. ProMMP-9 binding to the αM I 
domain in the presence of peptides was studied as described by immobilizing the I domain 
on microtiter wells and detecting bound MMP-9 with a monoclonal antibody to MMP-9 
(clone GE-213, NeoMarkers). ProMMP-9 was competed with peptides or chemicals. 
Gelatin binding to the proMMP-9/αMβ2 integrin complex was studied by immobilizing the 
integrin αMβ2 or αIIbβ3 as a control. ProMMP-9 was incubated for 2 h and the unbound 
proMMP-9 was washed away. Biotinylated gelatin was allowed to bind and was detected 
with streptavidin-peroxidase. The αM I domain binding to proMMP-9 was also studied by 
immobilizing the MMP. Briefly, the catalytically inactive proMMP-9-∆HC-E402Q mutant 
was prepared via site-directed mutagenesis from the wild-type proMMP-9-∆HC and coated 
on microtiter wells. Soluble αM integrin I domain-GST fusion (2.5 µg/ml) was added in the 
presence or absence of peptides or compounds and incubated for one hour. Bound GST 
fusion was detected with anti-GST antibody and peroxidase-conjugated anti-goat antibody.  
 
Gelatin and CBD binding assays. Recombinant CBD or human plasma fibronectin 
(Calbiochem) was immobilized in microtiter wells. The wells were saturated with 1% BSA-
PBST. Biotinylated gelatin was added with or without the peptides at the concentrations 
indicated or with an excess of unlabelled gelatin and allowed to bind for 1 h. Bound gelatin 
was detected with streptavidin-peroxidase. CBD binding to immobilized fibronectin, the 
110-kDa fragment of fibronectin (Upstate Biotechnology) or urea-denaturated human 
plasma vitronectin (1µg/well) was studied using biotinylated CBD (5µg/ml) in 1% BSA-
PBST in the presence or absence of 20 µM peptides. 
 
Immunoprecipitation and western blotting. HT1080 cells were treated with 50 nM PDBu 
for 3 h in serum-free medium, washed with PBS and lysed in 10 mM Tris-HCl (pH 8.0)/140 
mM NaCl/1% Triton X-100/1 mM PMSF followed by immunoprecipitation with anti-uPAR 
(399R, American Diagnostica, Greenwich, CT) or anti-MMP-9 (H-129, SantaCruz 
Biotechnology) or a control IgG. Integrins were immunoprecipitated with chain-spesific 
anti-integrin cytoplasmic domain antisera. The immunoprecipitates were resolved on an 8% 
SDS-PAGE gel, blotted and detected with anti-MMP-9 antibodies. 
 
Immunofluorescence. HT1080 cells were allowed to adhere on vitronectin (10 µg/ml) in 
serum-free DMEM. Directional migration of the cells was stimulated by overlaying the cells 
with 0.5% agarose in DMEM and adding 5 µl FBS with PDBu (20 nM final concentration) 
to the one end of the wells. Cells were cultured overnight, washed with PBS, fixed with 
paraformaldehyde, permeabilized, and stained with the monoclonal anti-uPAR antibody 
(Ab3937, American Diagnostica) or anti-β5 integrin IA9 and polyclonal MMP-9 antibodies 
(H-129). 
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Pericellular proteolysis. Microtiter wells were coated with a mixture of fibronectin (10 
µg/ml) and FITC-labelled gelatin (100 µg/ml) followed by saturation with 1% BSA in PBS. 
HT1080 cells (50 000 in 100 µl 0.1%BSA/DMEM) were incubated in the presence of 20 
nM PDBu and the peptides or the MMP-2/MMP-9 selective inhibitor InhI (Calbiochem). As 
a control non-activated cells and medium without the cells were used. Gelatinolysis was 
measured as the increase of fluorescence from an aliquot of the conditioned medium. 
 
uPAR clevage. Recombinant soluble human uPAR (suPAR, R&D Systems) was digested 
with trypsin-activated MMP-9 in the presence of 10 µg/ml aprotinin with or without 10 mM 
EDTA. The samples were incubated for 16 hours in 37°C and analyzed by western blotting 
with anti-uPAR antibodies. uPAR cleavage on the surface of HT1080 cells, THP-1 or OCI-
AML-3 cells was studied in a serum-free medium with or without 20 nM PDBu for 48 h in 
the presence or absence of inhibitors. The cells were washed with PBS, incubated with 50 
mM glycine-HCl (pH 3.0)/100 mM NaCl to extract cell surface bound urokinase-
plasminogen activator (uPA) and MMPs, and neutralized with 500 mM Hepes (pH 7.5)/100 
mM NaCl. Membrane proteins were enriched by Triton X-114 phase separation and 
analyzed by western blotting with antibodies to uPAR. 
 
125I-C domain binding to CS-1 melanoma cells. The MMP-9 C domain was labelled with 
125I to a specific activity of 0.06 µCi/pmol. The labelled domain retained 40% of the CRV 
peptide-binding activity as shown by the phage-binding assay. The CS-1 cells were washed 
with 2.5 mM EDTA in PBS and suspended in 20 mM Hepes (pH 7.5)/150 mM NaCl/1 mM 
MnCl2/0.2 mM CaCl2/0.5% BSA. After a preincubation of 1.5x106 cells on ice for 30 min 
with the competitors, 125I-labelled C domain (1x106 cpm) was added and incubated for three 
hours on ice. The cells were transferred to tubes containing 200 µl of dibutyl 
phthalate/cyclohexane mixture (23:2 vol/vol), centrifuged 7500xg for 10 minutes and snap-
frozen. The bottom of the tube containing the cells were cut and analyzed with a gamma-
counter. 
 
Human tumor xenograft growth in vivo. The animal studies were approved by the ethical 
committee of Helsinki University. HSC-3 tumors were established by administering 5x106 
tumor cells in PBS in both flanks of the Hsd:Athymic Nude-nu mice. After three days, the 
mice received five daily injection of 0.8 mg/ml CRV or the scrambled peptide or the vehicle 
(PBS) in a 200 µl volume. Three-dimensional caliper measurements were taken twice a 
week and the tumor volumes calculated. Mice were sacrificed when the tumor volume 
reached 1000 mm3. For the staining of the tumor vasculature, frozen tissue sections were 
stained with anti-CD31 antibody (MEC 13.3, BD Biosciences). 
 
Small molecule compound library screening. A combinatorial library of 10 000 small 
molecules was purchased from ChemBridge (San Diego, CA). A competition assay with the 
DDGW peptide bearing phage was set up by immobilizing 20 ng/well recombinant αM I 
domain-GST fusion in 96-well plates. The compounds were used in pools comprising eight 
compounds, each at a 5 µM concentration and DMSO at a 1.25% concentration. After 
preincubation of the compounds in the wells, DDGW phage was added (3x108 transducing 
units/well). Phage binding was detected with an anti-phage antibody and pools with 
inhibitory activity were re-tested as single compounds. 
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RESULTS AND DISCUSSION 
 
Brief descriptions of the main results are given together with additional views that are not 
emphasized in the original publications due to space limitations. Detailed discussions are 
found in the original publications. 
Biosynthesis of phage display peptides (I, III-IV). 
 
Inteins were examined as a fusion partner for phage display peptide expression in E. coli. A 
pH/temperature cleavable intein was used to obtain cyclic disulfide-bonded peptides, thus 
avoiding the use of thiol compounds. As a proof of principle, the gelatinase inhibitor peptide 
CTTHWGFTLC (CTT) was cloned and expressed. Synthetic and recombinant CTT peptides 
were identical in all gelatinase inhibition assays thus validating the intein expression 
strategy for the phage display peptides. Both peptides inhibited MMP-2 with an IC50 of 20 
µM. The significance of the intein expression system is that is allows rapid preparation of 
soluble peptides after a phage display selection. This markedly helps the analysis of phage 
binding specificity and allows initial characterization of the usefulness of the selected 
peptides. We also prepared recombinant single alanine mutants from the CTT peptide to 
study which amino acid residues are critical for the gelatinase inhibitory activity. The 
central amino acids Trp, Gly and Phe were found to be the most critical, whereas other 
mutations reduced the activity less than 20 %. With the knowledge that tryptophan is the 
most essential residue for gelatinase activity we aimed at replacing this residue with 
unnatural analogues in order to improve the activity of the CTT peptide. We further 
designed universal primers, which allow direct PCR-based cloning of phage-displayed 
peptides into the intein vector. These primers incorporate ADGA and GAAG peptide 
sequence into the N- and the C-terminus of the expressed peptide, respectively. The 
universal primers were used in subsequent phage display selections where the DDGW, PPC 
and CRV peptides were identified. 
 
Increase of serum stability of gelatinase inhibitor peptide CTT by 
incorporation of a 5-fluorotryptophan (I) 
 
Unnatural amino acids have not been previously incorporated into recombinant peptides. 
We isolated a tryptophan auxotrophic mutant E. coli from a library of MuA transposition 
mutagenized bacteria. With this bacterial strain designated ER2566/Trp82 and the intein 
expression system, we were able to obtain peptides containing 5- and 6-fluorotryptophan 
and 5-hydroxytryptophan. None of these modified peptides showed a better gelatinase 
inhibitory activity than the parental CTT peptide. As the analogue containing peptides may 
be proteolytically more stable than peptides containing only normal amino acids, we studied 
the stability of the peptides in human serum by immunoblotting. Unfortunately, only the 
stability of the 5F-Trp CTT could be analyzed as the other analogue containing peptides 
were not recognized by an anti-CTT peptide antibody. The 5F-Trp CTT peptide was found 
to be 6-fold more stable than the parental peptide. It was further found to be a more potent 
inhibitor of HT1080 fibrosarcoma cell invasion in normal human serum, but not in heat-
inactivated fetal bovine serum, apparently due to the increased serum stability. In this assay, 
the 6F-Trp CTT was also included, but did not show any beneficial effect compared to the 
parental CTT peptide. 
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Incorporation of amino acid analogues into phage display libraries (II) 
 
We reasoned that it would be even more advantageous to incorporate amino acid analogues 
into phage display libraries than into preselected peptides. This would allow direct isolation 
of peptides with improved activity and/or stability. We thus isolated auxotrophic mutants of 
E. coli MC1061. This strain was selected as it is commonly used for phage library 
preparation and also as it is naturally auxotrophic for leucine. The isolated tryptophan and 
methionine auxotrophs were further modified by adding a F pilus resulting in strains 
designated MB5F and MB64F, respectively. Formation of infective phage particles in the 
presence of various amino acid analogues was then studied. The fluorinated tryptophan 
analogues well supported the phage production. Norleucine, a methionine analogue, was 
also well incorporated and supported the production of infective phage particles. Leucine 
analogue incorporation was unsuccessful. The incorporation of tryptophan analogues was 
directly confirmed by the distinct fluorescence emission spectra of the fluorotryptophan 
containing phage particles. 
 
We prepared a 5F-Trp and 6F-Trp containing peptide library by infecting our standard 
CX7C and CX8C libraries into the MB5F strain. The resulting library now containing an 
extended amino acid repertoire was used in a biopanning with MMP-2 and MMP-9 C-
terminal domains. After three rounds of selection with the fluorophage library, the MMP-9 
C domain showed a 19-fold enrichment compared to the BSA control. Out of nine peptides, 
there were four containing a tryptophan residue, thus a potential fluorotryptophan. Although 
we were successful in the incorporation of amino acid analogues, this method is still in its 
infancy. A limiting factor is that only some amino acid analogues are incorporated thus 
constraining the diversity of the libraries that may be constructed. However, even a single 
amino acid analogue may significantly change the properties of the polypeptides (Hsieh et 
al., 1987; Tang et al., 2001; Tang and Tirrell, 2001). To further improve the system, the 
phage infectivity of the auxotrophic hosts should also be increased. Despite these 
limitations, this concept offers important advantages for the development of more diverse 
peptide libraries. 
 
Inhibition of MMP-9 interaction with αM integrin I domain by phage display 
peptides containg a DDGW motif (III) 
 
It has been previously identified that proMMP-1 binds to the α2 integrin I domain (Dumin et 
al., 2001) and that the binding involves the hemopexin-like C-terminal domain and the 
adjacent linker region in MMP-1 (Stricker et al., 2001). We thus investigated if leukocyte 
integrin I domains could bind MMPs. Furthermore, we were interested in developing 
peptide inhibitors for such an interaction. Biopanning with αM integrin I domain identified a 
predominant peptide motif with (D/E)(D/E)(G/L)W sequence. Similarity search to this motif 
identified that many MMPs have a related, well-conserved sequence present in their 
catalytic domain, MMP-2 and MMP-9 showing the best matches with the phage sequences. 
The suspected binding site in the catalytic domain was further confirmed in a pepspot 
membrane assay spanning the whole proMMP-9 sequence. The peptide containing the 
(D/E)(D/E)(G/L)W-like sequence was the dominant peptide motif binding to the αM I 
domain.  
 
The αMβ2 integrin is a highly promiscuos receptor binding a multitude of proteins and other 
biomolecules including DNA. The ability to bind multiple ligands has been attributed to the 
 57
sequence Lys245-Arg261 present in the I domain (Yakubenko et al., 2002). We thus examined 
other known αM integrin ligands for the occurrence of (D/E)(D/E)(G/L)W-like sites, which 
could mediate binding to the αM I domain. The peptides containing similar sites were 
synthesized on a pepspot membrane and analyzed for the αM I domain binding. Peptides 
from thrombospondin-1, myeloperoxidase, catalase and complement protein iC3b avidly 
bound the αM I domain. If the negative charges were changed to alanines, the binding 
activity of these peptides was lost. These findings suggest that a similar binding mechanism 
is used also for other proteins than the MMPs and represent a common αM integrin 
recognition motif. Supporting our results, it has been shown that elastase competes with 
iC3b binding to αMβ2 (Cai and Wright, 1996). Similarly, we observed competition of αM I 
domain-binding iC3b peptide with the phage peptide. 
 
The ADGACILWMDDGWCGAAG peptide (DDGW) binding to the αM I domain was 
chosen as a model peptide due to its high activity and favorable solubility properties. The 
progelatinases bound to intact β2 integrins and recombinant αM and αL I domains in vitro. 
Curiously, proMMP binding to αMβ2 integrin was about twice as strong as the binding to the 
αM I domain, suggesting that other interactions outside the DDGW-like motif may augment 
the binding. The I domain mediated binding was inhibited by the DGGW peptide in a dose 
dependent manner, the IC50 value being about 25 µM. The interaction of proMMP-9 with 
the I domain was not inhibited by lovastatin, a small-molecule antagonist of αL integrin I 
domain. Interestingly, although the binding of proMMP-9 to the αMβ2 integrin was inhibited 
by the cation chelator EDTA, DDGW-peptide bearing phage binding to the I domain was 
cation independent (data not shown), similarly to the proMMP-1 binding to the α2 I domain 
(Dumin et al., 2001). 
 
We also investigated the effect of the DDGW peptide on the adhesion and migration of 
THP-1 monocytic cells. Although activated THP-1 cells were able to bind to the DDGW 
peptide immobilized in microtiter wells, DDGW could not inhibit adhesion to the classical 
αMβ2 ligands fibrinogen and ICAM-1. However, at a 200 µM concentration DDGW peptide 
potently inhibited THP-1 migration on a synthetic LLG-C4-GST coating with a similar 
potency as the CTT peptide. DDGW had no effect on the migration of HT1080 
fibrosacroma cells, which do not express β2 integrins. However, HT1080 migration could be 
inhibited with the CTT peptide. In addition we observed that MMP-9 secretion or release 
from THP-1 cells is stimulated by the DDGW peptide apparently as a result of direct 
binding to the αM I domain. 
 
Identification of domain-specific ligands of MMP-9 that inhibit tumor cell 
migration and invasion (IV) 
 
In order to charaterize the molecular interactions of MMP-9 in tumor cells, we performed 
biopanning with proMMP-9. Two new peptide motifs were isolated in the screening, one 
with a CG(Ar)GR(Ar)(S/Q)PPC motif, where Ar is an aromatic amino acid, and a single 
peptide with CRVYGPYLLC sequence. These peptides did not compete with the CTT 
peptide binding and we identified that the first motif, represented by a CGYGRFSPPC 
(PPC) peptide, was a ligand for the collagen-binding domain (CBD) of gelatinases. The PPC 
peptide inhibited gelatinolysis by MMP-2 and MMP-9. The CRVYGPYLLC (CRV) peptide 
was found to be a ligand for the C-terminal domain (C domain). This was confirmed by 
phage binding to the recombinant C domain. Biopanning with the same domain identified 
similar peptides with a CRXYGPXXXC motif. The CRV peptide-bearing phage selectively 
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bound proMMP-9, but not proMMP-2 and proMMP-3. However, weak but specific binding 
to the recombinant MMP-2 C-terminal domain was observed. Importantly, the CRV peptide 
did not have any effect on the gelatinolytic activity of MMP-9 in vitro. 
 
We found a high sequence similarity between the PPC peptide and the matrix proteins 
fibronectin and vitronectin. The PPC-like sequence in fibronectin was located in the C-
terminal heparin binding domain. The CBD of MMP-9 was found to bind to intact 
fibronectin but not to a 110-kDa fragment of fibronectin lacking the C-terminal domain. The 
CBD also bound to vitronectin, but less strongly, perhaps because vitronectin in our studies 
was in the urea-denaturated form. Interestingly, the PPC-like site in fibronectin with a 
TTPNSLLVSWQPPRARIT sequence is adjacent and partially overlapping the heparin-
binding WQPPRARI sequence previously shown to have focal adhesion promoting activity 
(Woods et al., 1993). Furthermore, the WQPPRARI peptide is able to stimulate expression 
of MMP-1 and MMP-9 in fibroblasts plates on a fibronectin fragment lacking the heparin-
binding domain. This stimulation is mediated by α5β1 and α4β1 integrins (Huhtala et al., 
1995). We did not find evidence that PPC would act like the WQPPRARI peptide, because 
the active part of this peptide is the PRARI sequence (Woods et al., 1993). MMP-2 can 
cleave fibronectin in the heparin-binding domain. Curiously, this cleavage exposes an anti-
adhesive site for integrins, which suppresses cell adhesion (Watanabe et al., 2000). 
 
We evaluated the effect of the various gelatinase-binding peptides on HT1080 fibrosarcoma 
cell invasion through matrigel as well as THP-1 cell migration on the LLG-C4-GST coating. 
All domain specific peptides, but not the scrambled control peptides inhibited migration and 
invasion. The activity of the CRV peptide was comparable to the CTT peptide whereas the 
PPC peptide required slightly higher concentrations to obtain the same efficiency. This data 
indicated that all three domains of the gelatinases are needed for efficient cell migration. 
The effect of the CTT and PPC could be explained by inhibition of gelatinase activity. 
Further experiments were conducted to identify the mechanism how CRV inhibits cell 
migration and invasion. Interestingly, although CRV could not inhibit gelatinase activity in 
vitro, this peptide inhibited gelatinolysis by HT1080 cells to similar extent than CTT and 
PPC. Despite the fact that MMP-9 is rarely seen in the active form on the cell surface, we 
considered the possibility that CRV could affect the activation of MMP-9. This assumption 
was based on the role of C-terminal domain in the activation of MMP-2. Indeed, we found 
that plasminogen-mediated cellular activation of MMP-9 was reduced in the presence of 
CRV. CRV also inhibited MMP-2 activation at higher concentrations consistent with the 
data that it weakly binds to the C-terminal domain of MMP-2. 
 
MMP-9 interacts with the urokinase-plasminogen activator receptor and the 
integrin β chain (IV) 
 
The effect of the CRV peptide on plasminogen-mediated activation prompted us to examine 
potential interaction of MMP-9 with the urokinase-plasminogen activator receptor (uPAR). 
Both molecules are important players in tumor invasion. We found a physical interaction of 
these molecules by immunoprecipitation in HT1080 and THP-1 cells. Furthermore, MMP-9 
could cleave the uPA-binding domain from uPAR in vitro. uPAR cleavage has also been 
observed on the cell surface, and this cleavage can be inhibited with a broad-spectrum MMP 
inhibitor BB-94 (Koolwijk et al., 2001). We found that a gelatinase-selective small-
molecule inhibitor and the CTT peptide inhibited the cellular cleavage of uPAR. 
Importantly, the cleaved form of uPAR is found in invasive transplanted tumors in mice 
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(Solberg et al., 1994). Moreover, appearance of the fragmented uPAR is associated with the 
presence of tumor cells in acute myeloid leukemia (Mustjoki et al., 2000). These data and 
our findings that uPAR and MMP-9 associate in fibrosarcoma and leukemic cells indicates 
that the functional interplay of uPA/uPAR and MMP-9 may be a critical determinant in 
many types of cancer. 
 
Given that uPAR and MMPs can interact with several integrins, we examined the possible 
integrin interactions of MMP-9 in HT1080 cells by immunoprecipitation. ProMMP-9 could 
be immunoprecipitated with antibodies to α5 and β5 integrins, suggesting that the major 
integrin receptors in these cells are α5β1 and αVβ5. It has been observed that the integrin 
associations of MMPs and uPAR are regulated by the matrix components where the cells 
are attached. In a serum-containing cell culture medium, the plastic becomes coated with 
fibronectin and vitronectin, the ligands for α5β1 and αVβ5, respectively. It is thus not 
surprising to find that MMP-9 was associated with these receptors. As the C-terminal 
domains of MMP-1 and MMP-2 have been implicated in the integrin binding, we looked for 
CRV-like sequences in the integrins. A CRV-like sequence was found in the integrin-
epidermal growth factor-like domain 2 of the integrin β chains. The highest similarities were 
found with the β5 and β6 integrins and a recombinant fragment of the β5 integrin chain 
containing the CRV-like sequence bound to the C domain of MMP-9 and inhibited the 
invasion of HT1080 fibrosarcoma cells. 
 
Despite the CRV peptide is not a direct inhibitor of gelatinases, it could potently inhibit 
pericellular proteolysis. To extend these findings, the effect of the CRV peptide was studied 
in a human tumor xenograft model. In this assay, CRV significantly inhibited human tongue 
squamous cell carcinoma xenograft growth prolonging the survival of the tumor-bearing 
mice. The scrambled control peptide was not effective. The inhibition of tumor growth 
could at least partly be accounted for inhibition of angiogenesis, as the CRV-treated tumors 
had a less developed vasculature as revealed by the endothelial marker CD31 
immunostaining. In conclusion, this data suggest that compounds inhibiting MMP-9 
interactions rather than direct catalytic activity may have a potential in cancer therapy. 
 
Identification of a small molecule inhibitor of αMβ2 integrin-dependent 
leukemia cell migration (V) 
 
Because peptides are not optimal therapeutic agents due to their proteolytic susceptibility 
and rapid clearance in vivo, we aimed at screening for small molecules that would act 
analogously to the peptides but be more suitable for drug-development. A competition assay 
with the DDGW peptide bearing phage was set up and a commercially available 
combinatorial library was screened. Nineteen compounds were identified as inhibitors of 
DDGW-peptide binding, fourteen of which had a common 2-thioxothiazolidin-4-one 
structure. The best compound was about six times more active than the soluble DDGW 
peptide in the phage assay, having an IC50 value of 0.4 µM. Surprisingly, these compounds 
could not compete with proMMP-9 binding to the αM I domain, although they potently 
inhibited phage binding. In contrast, they enhanced the binding of the αM I domain to 
proMMP-9 and fibrinogen suggesting that they stabilize the active conformation of the I 
domain. 
 
The unexpected difference in the biological activity of DDGW and the chemical compounds 
can be traced to the molecular nature of these inhibitors. DDGW is a highly charged 
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peptide, which is typical for the integrin ligands. Indeed, all αL I domain binding small 
molecules described are uncharged and they bind to the same site, distinct from the ligand 
binding site of the I domain. This suggests that it is highly difficult to obtain direct 
competitors for integrin ligands and other charged peptides from combinatorial libraries. 
Thus, the use of phage display as a tool to screen for integrin ligands appears to provide 
novel ligands that cannot be easily found using combinatorial chemistry. On the contrary, 
phage-display peptides binding via hydrophobic interactions should readily yield direct 
competitors. 
 
The most potent compound IMB-10 made αMβ2 integrin-expressing cells partially resistant 
to detachment by the cation chelator EDTA. In addition, it was a potent inhibitor of β2 
integrin mediated migration of THP-1 and OCI-AML-3 leukemia cells. The IMB-10 
interfered only with β2 integrin-dependent migration, as there was no effect on the migration 
of HT1080 fibrosarcoma cells. The ability of IMB-10 to inhibit cell migration on fibrinogen 
was independent on gelatinase activity, as a small-molecule gelatinase inhibitor did not 
block cell migration in these assays. Furthermore, IMB-10 did not inhibit pericellular 
gelatinase-dependent proteolysis of uPAR. This data indicate that the inhibition of leukemia 
cell migration by IMB-10 is caused primarily due to enhanced adhesion and not by 
inhibition of integrin-regulated gelatinase activity. 
 
The activation state of the I domains is regulated by the movement of the C-terminal α-
helix. In accordance with this, we found that mutations in the hydrophobic socket 
accommodating the C-terminal activity-regulating helix abolished the ability of the I domain 
to be induced by IMB-10. In contrast, mutations in the C-terminal helix resulted in partially 
active I domain, which could be further induced by the chemical. We additionally confirmed 
that the Lys245 residue speculated to be important for progelatinase binding was indeed 
important. High affinity binding to proMMP-9 could not be induced with the Lys245Ala 
mutant I domain.   
 
The identified αM I domain binding compounds, although being more potent than the 
DDGW peptide as an inhibitor of leukemic cell migration, are still relatively inefficient in 
comparison to optimized drug-molecules. It is interesting to note that from a diversity of 10 
000 small-molecules, one can identify compounds that are at least as active as peptides 
originally derived from a library of over 108 members. We have additionally screened the 
same compounds with the aid of the CRV peptide. From this screen, one potent hit was 
identified (M. Björklund and E. Koivunen, unpublished). The next step with the IMB-10 is 
to conduct structure-activity relationship studies to identify more active derivatives and to 
evaluate their in vivo activity. 
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CONCLUDING REMARKS 
 
 
Phage display is a straightforward route from basic protein-protein interaction studies to 
drug discovery process. Although knockout mice are considered as the golden standard 
when evaluating the function of different proteins in vivo, phage display peptides offer a 
complementary method by pharmacological inhibition of the protein function. In addition to 
the potential to rapidly screen for ligands for new targets and for the identification of 
protein-protein interactions, the peptides may be used in structural studies to identify 
binding sites for therapeutic small-molecules or used as a starting point in the synthesis of 
peptidomimetics. Novel means that would bring the peptide leads closer to the clinically 
useful drug molecules would significantly shorten the time and expenses needed for drug 
development. This work demonstrates that this goal may be attainable by using nonnatural 
amino acids or by selecting small-molecule compounds that mimick the action of the phage 
display peptides. 
 
In this study, we used phage display of random peptides to understand gelatinase-mediated 
cell migration and invasion. We identified multiple interactions of gelatinases and inhibition 
of these interactions with the peptides was successfully used to block cancer cell migration 
and invasion. A favourable outcome could not only be obtained by peptides that inhibit 
catalytic activity of the gelatinases such as the CTT and PPC peptides, but also with the 
DDGW and CRV peptides, which block cell surface interactions of the gelatinases. Our 
results provide further evidence for the previous reports indicating a critical role of 
pericellular MMP activity in cell migration (Brooks et al., 1998; Brooks et al., 1996; Dumin 
et al., 2001). A hypothetical model of gelatinase-mediated cell migration/invasion 
machinery can be proposed based on these findings (Figure 9). We propose a name 
“invadosome” for this protein complex. In addition to the interactions characterized in our 
laboratory, inhibitors of interactions between uPA and uPAR as well as uPAR and integrins 
have been identified by phage display (Goodson et al., 1994; Wei et al., 1996). The 
invadosome is likely a short-lived complex where MMPs, integrins, uPA/uPAR, matrix 
proteins and possibly other proteins are brought together, when the cells encounter a non-
degraded extracellular matrix and need to invade and migrate. Indeed, many integrin ligands 
are substrates for the integrin-associated proteinases. By definition, the cell migration 
machinery must be a highly dynamic complex to be able to perform the multiple tasks that 
are necessary for migration and invasion. The composition of the complex must also vary 
depending on the extracellular matrix ligands. Although this study does not provide direct 
evidence that all the components indicated in the invadosome complex would bind at the 
same time, the differential binding sites identified suggest that they might do so. Another 
point to note is that the proteinases have functions independent on their proteolytic activity. 
This has been well established with the uPA/uPAR system (Blasi and Carmeliet, 2002) and 
evidence is accumulating that the MMPs function similarily (Cao et al., 2004; Sanceau et 
al., 2003). 
 
Although MMP-1, -2 and –9 bind to integrins, the interaction mechanisms appear to differ 
slightly. The binding of MMP-2 and MMP-9 to αVβ3 and αVβ5 appear to be the most similar. 
Both MMPs bind through their C-terminal domain to the integrin outside the integrin 
ligand-binding site (Brooks et al., 1998 and this study). However, the small-molecule 
inhibitor inhibiting the MMP-2/αVβ3 interaction binds to the integrin (Boger et al., 2001; 
Silletti et al., 2001), whereas the CRV peptide binds to the MMP-9 indicating that the exact 
binding mechanism need not to be the very same. The integrin α I domains are the binding 
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sites for MMP-1 and MMP-9. Curiously, MMP-1 utilizes the C-terminal domain and the 
adjacent hinge region for α2 I domain binding (Stricker et al., 2001), whereas MMP-9 
catalytic domain interacts with the αM and αL I domains. Whether this is a functional 
adaptation to achieve cell-type specific regulation of MMP activity remains to be 
determined. 
 
Figure 9. The invadosome model. The molecular components interacting with each other 
are depicted. The invadosome regulates multiple proteolytic and nonproteolytic functions, 
which are required for controlled cell migration and invasion for example during intravastion 
of the tumor cells into the blood stream.  
 
Another issue is the relationship between the integrin activation-state and MMP binding. 
The α I domain containing integrins can exist in several conformations: 1) the inactive bent 
form with a closed headpiece containing the ligand binding regions; 2) extended form with 
closed headpiece and low affinity I domain; 3) extended form with open headpiece and low 
affinity I domain; 4) extended form with open headpiece and high affinity I domain 
(Shimaoka et al., 2003). The non-I domain integrins, such as αVβ3 and αVβ5 exist at least in 
the bent and the extendend conformation (Takagi et al., 2002; Xiong et al., 2001). The 
preliminary data obtained in this study indicates that the extended conformation of the 
integrin is required for the MMP C-terminal domain interaction. Whether MMPs can also 
bind to the bent form or the intermediate active forms remains to be clarified, but the ability 
of proMMP-9 to interact with the closed I domain suggests that this is possible. 
Furthermore, does activation of MMPs occur simultaneously or subsequently to integrin 
activation? Some studies have indicated that the activation of the proteases may occur 
concomitant with integrin ligand-binding and activation (Prager et al., 2003; Yan et al., 
2000). Investigations with activation state-specific integrin antibodies and antibodies 
specific for pro- and active MMPs could shed light on this matter. 
 
One of the major questions is whether the MMPs are a clinically relevant target for the 
therapeutic intervention in cancer and to what extent other diseases could be treated with the 
MMP inhibitors. Although over hundred small-molecules targeting the catalytic site of the 
MMPs have been synthesized, these compounds have limited specificity to individual 
MMPs and no significant success has been seen with these compounds in the clinical trials. 
At present, there is not sufficient knowledge on the role of individual MMPs in cancer. 
Hence, the decision, which MMP should be targeted still remains an educated guess. Even if 
such knowledge would be available, the conserved structural features of the MMPs indicate 
that it will be a considerable challenge to synthesize an active-site inhibitor with specificity 
to a single MMP. Additionally, the MMPs are typically required in the early stage of the 
 63
tumor progression, thus the best therapeutic window for the MMP inhibitors may be lost if 
the disease is not early diagnosed. 
 
It remains to be seen, whether the more selective active-site inhibitors, exosite inhibitors and 
inhibitors of protein-protein interactions such as those identified in this study appear to be 
any more successful as cancer therapeutics. Certainly a better knowledge on the role of 
MMPs in cancer progression is required to achieve this goal. For example, knowledge about 
the binding partners for the gelatinases alone is certainly incomplete. The recent finding that 
MMP-2 interacts with the chaperone protein Hsp90 in the extracellular space and that this 
interaction regulates tumor cell invasion is one indication that we do not yet understand the 
details about tumor cell migration and invasion (Eustace et al., 2004). Furthermore, 
blocking MMPs alone may not be sufficient to achieve an adequate clinical response. 
Hence, it is certainly worthwhile to consider the possibility of combination therapy with 
drugs affecting other functions of the cancer cells. Nevertheless, the peptides and chemicals 
identified in this study will hopefully be useful for further studies on the role of gelatinases 
in physiological and pathological conditions and to aid in the development of 
pharmacologically active agents to combat cancer and other diseases associated with 
excessive gelatinase activity. 
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